{"id":5677,"date":"2024-09-02T12:21:55","date_gmt":"2024-09-02T10:21:55","guid":{"rendered":"https:\/\/thoraxzentrum-ruhrgebiet.de\/%d8%a7%d9%84%d9%85%d9%86%d8%b4%d9%88%d8%b1%d8%a7%d8%aa\/%d9%85%d9%86%d8%b4%d9%88%d8%b1%d8%a7%d8%aa-%d8%a7%d9%84%d8%a3%d9%88%d8%b1%d8%a7%d9%85-%d8%a7%d9%84%d8%b5%d8%af%d8%b1%d9%8a%d8%a9\/"},"modified":"2026-10-21T14:41:06","modified_gmt":"2026-10-21T12:41:06","slug":"%d9%85%d9%86%d8%b4%d9%88%d8%b1%d8%a7%d8%aa-%d8%a7%d9%84%d8%a3%d9%88%d8%b1%d8%a7%d9%85-%d8%a7%d9%84%d8%b5%d8%af%d8%b1%d9%8a%d8%a9","status":"publish","type":"page","link":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/%d8%a7%d9%84%d9%85%d9%86%d8%b4%d9%88%d8%b1%d8%a7%d8%aa\/%d9%85%d9%86%d8%b4%d9%88%d8%b1%d8%a7%d8%aa-%d8%a7%d9%84%d8%a3%d9%88%d8%b1%d8%a7%d9%85-%d8%a7%d9%84%d8%b5%d8%af%d8%b1%d9%8a%d8%a9\/","title":{"rendered":"\u0645\u0646\u0634\u0648\u0631\u0627\u062a \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0635\u062f\u0631\u064a\u0629"},"content":{"rendered":"\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-7jn1tg-b5d655172b15d61c4c8c7eb1d4c66593\">\n#top .av-special-heading.av-7jn1tg-b5d655172b15d61c4c8c7eb1d4c66593{\npadding-bottom:10px;\n}\nbody .av-special-heading.av-7jn1tg-b5d655172b15d61c4c8c7eb1d4c66593 .av-special-heading-tag .heading-char{\nfont-size:25px;\n}\n.av-special-heading.av-7jn1tg-b5d655172b15d61c4c8c7eb1d4c66593 .av-subheading{\nfont-size:15px;\n}\n<\/style>\n<div  class='av-special-heading av-7jn1tg-b5d655172b15d61c4c8c7eb1d4c66593 av-special-heading-h1 blockquote modern-quote  avia-builder-el-0  el_before_av_textblock  avia-builder-el-first '><h1 class='av-special-heading-tag '  itemprop=\"headline\"  >\u0645\u0646\u0634\u0648\u0631\u0627\u062a \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0635\u062f\u0631\u064a\u0629<\/h1><div class=\"special-heading-border\"><div class=\"special-heading-inner-border\"><\/div><\/div><\/div>\n<section  class='av_textblock_section av-5cngzo-571dfc2a1e0011d0c4459db5af4aec58 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock'  itemprop=\"text\" ><p>\u0647\u0646\u0627 \u0633\u062a\u062c\u062f\u0648\u0646 \u0645\u0639\u0644\u0648\u0645\u0627\u062a \u062d\u0648\u0644 \u0645\u0646\u0634\u0648\u0631\u0627\u062a\u0646\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0635\u062f\u0631\u064a\u0629<\/p>\n<\/div><\/section>\n<div  class='togglecontainer av-4eu9jo-603240cd3a2a3c6bc6b8deedf6d536c7  avia-builder-el-2  el_after_av_textblock  avia-builder-el-last  toggle_close_all' >\n<section class='av_toggle_section av-30nmys-64ed3c382a8859747b89c3fa58b2f8ce'  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div role=\"tablist\" class=\"single_toggle\" data-tags=\"{All} \"  ><p id='toggle-toggle-id-1' data-fake-id='#toggle-id-1' class='toggler  activeTitle av-title-above '  itemprop=\"headline\"  role='tab' tabindex='0' aria-controls='toggle-id-1' data-slide-speed=\"200\" data-title=\"\u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0627\u062a\" data-title-open=\"\" data-aria_collapsed=\"Click to expand: \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0627\u062a\" data-aria_expanded=\"Click to collapse: \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0627\u062a\">\u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0627\u062a<span class=\"toggle_icon\"><span class=\"vert_icon\"><\/span><span class=\"hor_icon\"><\/span><\/span><\/p><div id='toggle-id-1' aria-labelledby='toggle-toggle-id-1' role='region' class='toggle_wrap  active_tc av-title-above' style='display:block;' ><div class='toggle_content invers-color '  itemprop=\"text\" ><p><strong>\u0627\u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0623\u0635\u0644\u064a\u0629:<\/strong><br \/>\n\u0627\u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0623\u0635\u0644\u064a\u0629:<\/p>\n<p><strong>2025<\/strong><br \/>\n1) Molasiotis A, Jordan K, Karthaus M, Dranitsaris G, Roeland EJ, Schwartzberg LS, Bonizzoni E, Brozos Vazquez E, Buchler T, Chen Y, Christoph DC, Garc\u00eda Alfonso P, Lu X, Majem M, Mavroudis D, Syrigos K, Tomlins E, Zhou Z, Zimovjanova M, Aapro MS (2025): \u062a\u062e\u0635\u064a\u0635 \u0627\u0644\u0648\u0642\u0627\u064a\u0629 \u0627\u0644\u0645\u0636\u0627\u062f\u0629 \u0644\u0644\u0642\u064a\u0621 \u0644\u0644\u0645\u0631\u0636\u0649 \u0630\u0648\u064a \u062e\u0637\u0631 \u0645\u0631\u062a\u0641\u0639 \u0644\u0644\u0642\u064a\u0621: \u0646\u062a\u0627\u0626\u062c \u062a\u062c\u0631\u0628\u0629 MyRisk. Ann Oncol \u0627\u0644\u0645\u062c\u0644\u062f 36 (\u0645\u0644\u062d\u0642): S1489-S1490\u060c 2801O. \u0639\u0631\u0636 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>2) Metzenmacher M, Thomas M, Griesinger F, de Wit M, Christoph DC, Gro\u00df-Ophoff-M\u00fcller CS, J\u00e4nicke M, Fleitz A, Zacharias S, Groth A, Ludwig P , Kursar M, Fuchs C, Innig R, Dietze G, Dechow LT, Sebastian M, Eberhardt WE (2025): \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a-\u0627\u0644\u0645\u0646\u0627\u0639\u064a \u0627\u0644\u0645\u0631\u0643\u0628 \u0645\u0642\u0627\u0628\u0644 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u0646\u0627\u0639\u064a \u0627\u0644\u0623\u062d\u0627\u062f\u064a \u0641\u064a \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0645\u0639 \u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0645\u0631\u062a\u0641\u0639\u0629 \u0644\u0640 PD-L1. \u0628\u064a\u0627\u0646\u0627\u062a \u0648\u0627\u0642\u0639\u064a\u0629 \u062c\u0631\u0649 \u062a\u062d\u0644\u064a\u0644\u0647\u0627 \u0628\u062a\u0642\u0646\u064a\u0629 \u062f\u0631\u062c\u0627\u062a \u0627\u0644\u0645\u064a\u0644 \u0645\u0646 \u062f\u0631\u0627\u0633\u0629 \u0633\u062c\u0644 \u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0633\u062a\u0628\u0627\u0642\u064a \u0645\u062a\u0639\u062f\u062f \u0627\u0644\u0645\u0631\u0627\u0643\u0632 (CRISP). Ann Oncol \u0627\u0644\u0645\u062c\u0644\u062f 36 (\u0645\u0644\u062d\u0642): S1171\u060c 2087eP. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>3) Eberhardt WEE, Passlick B, Groeschel A, Christoph DC, Grah C, Hoffknecht P, Ludwig P, Groth A, Lennartz C, Jaenicke M, Spring L, Seese B, Sebastian M, Griesinger F, Stuschke M, Thomas M (2025): \u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0641\u064a \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0644\u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u062a\u064a\u0646 II-III \u0641\u064a \u0623\u0644\u0645\u0627\u0646\u064a\u0627 \u062e\u0644\u0627\u0644 2018-24 (\u0627\u0644\u0633\u062c\u0644 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u0627\u0633\u062a\u0628\u0627\u0642\u064a CRISP\u060c AIO-TRK-0315). Ann Oncol \u0627\u0644\u0645\u062c\u0644\u062f 36 (\u0645\u0644\u062d\u0642): S1060\u060c 1841eP. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>4) Planchard D, S\u00e9bastien C, Mascaux C, Auliac J-B, Christoph DC, Bonomi L, Chella A, Carcereny E, Pons Tostivint E, Signorelli D, Beghdad F, Dialla O, Khan S, Popat S (2025): \u0623\u0646\u0645\u0627\u0637 \u0627\u0644\u062a\u0634\u062e\u064a\u0635 \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0644\u062f\u0649 \u0627\u0644\u0628\u0627\u0644\u063a\u064a\u0646 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0646\u0642\u064a\u0644\u064a \u0645\u0639 \u0637\u0641\u0631\u0629 BRAF V600E \u0641\u064a \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629: \u062f\u0631\u0627\u0633\u0629 \u062f\u0648\u0644\u064a\u0629 \u0648\u0627\u0642\u0639\u064a\u0629 \u0623\u0645\u0628\u064a\u0633\u0628\u064a\u0643\u062a\u064a\u0641 (OCTOPUS). J Thorac Oncol \u0627\u0644\u0645\u062c\u0644\u062f 20 \u0627\u0644\u0639\u062f\u062f 3 (\u0627\u0644\u0645\u0644\u062d\u0642 1)\u060c 87P. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2025.<\/p>\n<p>5) Molassiotis A, Jordan K, Karthaus M, Dranitsaris G, Roeland EJ, Schwartzberg L, Stimamiglio V, Alonzi A, Tilola SO, Bonizzoni E, Brozos V\u00e1zquez E, Buchler T, Cheng Y, Christoph DC, Garc\u00eda Alfonso P, Lu X, Majem M, Mavroudis D, Syrigos K, Tomlins E, Zhou Z, Zimovjanov\u00e1 M, Aapro M (2025): \u062a\u0639\u0632\u064a\u0632 \u0627\u0644\u0648\u0642\u0627\u064a\u0629 \u0645\u0646 CINV: \u0645\u0642\u0627\u0631\u0646\u0629 NEPA \u0645\u0642\u0627\u0628\u0644 \u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0627\u0644\u0642\u064a\u0627\u0633\u064a\u0629 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0630\u0648\u064a \u0639\u0648\u0627\u0645\u0644 \u062e\u0637\u0631 \u0645\u062a\u0639\u062f\u062f\u0629 \u0644\u0644\u0642\u064a\u0621 \u0627\u0644\u0630\u064a\u0646 \u064a\u062a\u0644\u0642\u0648\u0646 \u0639\u0644\u0627\u062c\u064b\u0627 \u0643\u064a\u0645\u064a\u0627\u0626\u064a\u064b\u0627 \u0645\u062a\u0648\u0633\u0637 \u0627\u0644\u0625\u062d\u062f\u0627\u062b \u0644\u0644\u0642\u064a\u0621 (MEC). \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062c\u0646\u0633\u064a\u0627\u062a \u0644\u0644\u0631\u0639\u0627\u064a\u0629 \u0627\u0644\u062f\u0627\u0639\u0645\u0629 \u0641\u064a \u0627\u0644\u0633\u0631\u0637\u0627\u0646 (MASCC)\/\u0627\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u062f\u0648\u0644\u064a\u0629 \u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0641\u0645 (ISOC) 2025.<\/p>\n<p>6) Girard N, Bar J, Christoph D, Field J Fietkau R, Garassino MC, Garrido Lopez P, Haakensen VD, Hiltermann JTJN, Kao SC, McDonald F, Mornex F, Moskovitz MT, Peters S, Siva S, Solomon B, Qiao X, Anand S, Chander P, Filippi AR (2025): \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0628\u0642\u0627\u0621 \u0644\u0645\u062f\u0629 5 \u0633\u0646\u0648\u0627\u062a \u0641\u064a \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0645\u0639 \u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 (D) \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a (CRT) \u0641\u064a \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u063a\u064a\u0631 \u0627\u0644\u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0633\u062a\u0626\u0635\u0627\u0644\u060c \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III (urNSCLC): \u0627\u0644\u0627\u0633\u062a\u062e\u0631\u0627\u062c \u0627\u0644\u0646\u0647\u0627\u0626\u064a \u0644\u0644\u0628\u064a\u0627\u0646\u0627\u062a \u0645\u0646 PACIFIC-R. J Thorac Oncol \u0627\u0644\u0645\u062c\u0644\u062f 30 \u0627\u0644\u0639\u062f\u062f 2 (\u0627\u0644\u0645\u0644\u062d\u0642 1)\u060c 190P. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0645\u0624\u062a\u0645\u0631 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a 2025.<\/p>\n<p>7) Planchard D, Couraud S, Mascaux C, Auliac JB, Christoph DC, Bonomi L, Chella A, Carcereny E, Pons-Tostivint E, Signorelli D, Beghdad F, Dialla O, Khan S, Popat S (2025): \u0623\u0646\u0645\u0627\u0637 \u0627\u0644\u062a\u0634\u062e\u064a\u0635 \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0644\u062f\u0649 \u0627\u0644\u0628\u0627\u0644\u063a\u064a\u0646 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0646\u0642\u064a\u0644\u064a \u0645\u0639 \u0637\u0641\u0631\u0629 BRAF V600E \u0641\u064a \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629: \u062f\u0631\u0627\u0633\u0629 \u062f\u0648\u0644\u064a\u0629 \u0648\u0627\u0642\u0639\u064a\u0629 \u0623\u0645\u0628\u064a\u0633\u0628\u064a\u0643\u062a\u064a\u0641 (OCTOPUS). J Thorac Oncol \u0627\u0644\u0645\u062c\u0644\u062f 30 \u0627\u0644\u0639\u062f\u062f 2 (\u0627\u0644\u0645\u0644\u062d\u0642 1)\u060c 86P. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0645\u0624\u062a\u0645\u0631 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a 2025<\/p>\n<p><strong>2024<\/strong><br \/>\n1) Kraus FM, Traut A, Nilius G, Volmerig J, Koziorowski A, St\u00f6ver I, Grabellus F, Stahl M, Christoph DC (2024): \u0633\u0631\u0637\u0627\u0646 \u063a\u062f\u064a \u0631\u0626\u0648\u064a \u0645\u0639 \u062a\u0645\u0627\u064a\u0632 \u0645\u0639\u0648\u064a (PAED) \u062f\u0648\u0646 \u062a\u0639\u0628\u064a\u0631 TTF-1 \u0647\u0648 \u0646\u0645\u0637 \u0641\u0631\u0639\u064a \u0646\u0627\u062f\u0631 \u062c\u062f\u064b\u0627 \u0645\u0639 \u062e\u064a\u0627\u0631\u0627\u062a \u0639\u0644\u0627\u062c \u0645\u062d\u062f\u0648\u062f\u0629 \u0648\u0625\u0646\u0630\u0627\u0631 \u0633\u064a\u0626. Oncology \u0642\u064a\u062f \u0627\u0644\u0637\u0628\u0627\u0639\u0629.<\/p>\n<p>2) Ferentinos K, Traut A, Gubelt L, Nilius G, Czyborra PB, Nusch A, Langer W, N\u00fcckel H, Hannig CV, Stahl M, Christoph DC (2024): \u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629 \u0648\u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0644\u062f\u0648\u0633\u062a\u0627\u0643\u0632\u064a\u0644 \u0628\u0627\u0644\u0627\u0634\u062a\u0631\u0627\u0643 \u0645\u0639 \u0646\u064a\u0646\u062a\u064a\u062f\u0627\u0646\u064a\u0628 \u0623\u0648 \u0631\u0627\u0645\u0648\u0633\u064a\u0631\u0648\u0645\u0627\u0628 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a-\u0627\u0644\u0645\u0646\u0627\u0639\u064a \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0646\u0642\u064a\u0644\u064a. J Oncol Res Ther 9: 10232. DOI: 10.29011\/2574-710X.10232.<\/p>\n<p>3) Kraus FM, Traut A, Gubelt L, Nilius G, Volmerig J, Koziorowski, St\u00f6ver I, Grabellus F, Stahl, M, Christoph DC (2024) \u0645\u0642\u0627\u0631\u0646\u0629 \u0645\u062b\u0628\u0637\u0627\u062a \u0646\u0642\u0627\u0637 \u0627\u0644\u062a\u0641\u062a\u064a\u0634 \u0643\u0639\u0644\u0627\u062c \u0623\u062d\u0627\u062f\u064a \u0643\u062e\u0637 \u0623\u0648\u0644 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 NSCLC \u0630\u0648\u064a \u062a\u0639\u0628\u064a\u0631 \u0645\u0631\u062a\u0641\u0639 \u0644\u0640 PD-L1. J Oncol Res Ther 9: 10228.<\/p>\n<p>4) Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N (2024): \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0645\u0639 \u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 NSCLC \u063a\u064a\u0631 \u0627\u0644\u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0633\u062a\u0626\u0635\u0627\u0644 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III: \u062a\u062d\u0644\u064a\u0644 \u0645\u0631\u062d\u0644\u064a \u0644\u0644\u0628\u0642\u0627\u0621 \u0627\u0644\u0643\u0644\u064a \u0645\u0646 PACIFIC-R. ESMO Open 9(6):103464.<\/p>\n<p>5) Neal J, Pavlakis N, Kim S-W, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, Lin Y-C, Huseni M, Ballinger M, Graupner V, Curran D, Vervaet P, Newsom-Davis T (2024): CONTACT-01: \u062a\u062c\u0631\u0628\u0629 \u0639\u0634\u0648\u0627\u0626\u064a\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III \u0644\u0623\u062a\u064a\u0632\u0648\u0644\u064a\u0632\u0648\u0645\u0627\u0628 + \u0643\u0627\u0628\u0648\u0632\u0627\u0646\u062a\u064a\u0646\u064a\u0628 \u0645\u0642\u0627\u0628\u0644 \u062f\u0648\u0633\u062a\u0627\u0643\u0632\u064a\u0644 \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0646\u0642\u064a\u0644\u064a \u0628\u0639\u062f \u0645\u062b\u0628\u0637 \u0646\u0642\u0627\u0637 \u0627\u0644\u062a\u0641\u062a\u064a\u0634 \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a. J Clin Oncol 42(20):2393-2403.<\/p>\n<p><strong>2023<\/strong><br \/>\n1) Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He H, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators (2023): SAPPHIRE: \u062f\u0631\u0627\u0633\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III \u0644\u0633\u064a\u062a\u0631\u0627\u0641\u0627\u062a\u064a\u0646\u064a\u0628 \u0645\u0639 \u0646\u064a\u0641\u0648\u0644\u0648\u0645\u0627\u0628 \u0645\u0642\u0627\u0628\u0644 \u062f\u0648\u0633\u062a\u0627\u0643\u0632\u064a\u0644 \u0641\u064a \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u063a\u064a\u0631 \u0627\u0644\u062d\u0631\u0634\u0641\u064a. Ann Oncol 35(1):66-76.<\/p>\n<p>2) Borchert S, Mathilakathu A, Nath A, Wessolly M, Mairinger E, Kreidt D, Steinborn J, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Mairinger FD (2023). \u062a\u0624\u062b\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0644\u064a\u0641\u064a\u0629 \u0627\u0644\u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0627\u0644\u0633\u0631\u0637\u0627\u0646 \u0641\u064a \u0627\u0644\u0628\u0642\u0627\u0621 \u0644\u062f\u0649 \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a: \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u062a\u0639\u0628\u064a\u0631 \u0627\u0644\u062c\u064a\u0646\u064a \u0627\u0644\u0631\u0642\u0645\u064a \u0648\u0646\u0645\u0648\u0630\u062c \u062a\u0639\u0644\u0645 \u0622\u0644\u064a \u0645\u064f\u0631\u0627\u0642\u064e\u0628. Int J Mol Sci. 24(15):12426.<br \/>\n3) Stahl MK, Ertl SW, Engelmeyer P, Heuer HC, Christoph DC (2023): \u062a\u0623\u062b\u064a\u0631 \u0627\u0644\u062a\u0642\u064a\u064a\u0645 \u0627\u0644\u0634\u064a\u062e\u0648\u062e\u064a \u0639\u0644\u0649 \u062a\u062d\u0645\u0644 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0645\u0631\u0643\u0628 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0623\u0643\u0628\u0631 \u0633\u0646\u064b\u0627 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0633\u0631\u0637\u0627\u0646 \u0645\u062a\u0642\u062f\u0645: \u062a\u062d\u0644\u064a\u0644 \u0623\u0632\u0648\u0627\u062c \u0645\u062a\u0637\u0627\u0628\u0642\u0629. Oncol Res Treat. 46(3):100-105.<\/p>\n<p><strong>2022<\/strong><br \/>\n1) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022): \u062e\u0635\u0627\u0626\u0635 \u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0628\u0642\u0627\u0621 \u062f\u0648\u0646 \u062a\u0642\u062f\u0645 \u0627\u0644\u0645\u0631\u0636 \u0641\u064a \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 NSCLC \u063a\u064a\u0631 \u0627\u0644\u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0633\u062a\u0626\u0635\u0627\u0644 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III \u0627\u0644\u0630\u064a\u0646 \u062a\u0644\u0642\u0648\u0627 \u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a: \u0646\u062a\u0627\u0626\u062c \u062f\u0631\u0627\u0633\u0629 PACIFIC-R. J Thorac Oncol. 18:181-193<\/p>\n<p>2) Zhang Z, Xie S, Cai W, Hong ZN, Yang C, Lin Y, Zhu J, Lin Z, Christoph DC, Bohnenberger H, Kepka L, Brueckl WM, Van Houtte P, Kang M, Lin J (2022): \u0645\u062e\u0637\u0637 \u0646\u0648\u0645\u0648\u063a\u0631\u0627\u0645 \u0644\u0644\u062a\u0646\u0628\u0624 \u0628\u0627\u0644\u0628\u0642\u0627\u0621 \u062f\u0648\u0646 \u0646\u0643\u0633 \u0648\u062a\u062d\u0644\u064a\u0644 \u0641\u0627\u0626\u062f\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0641\u064a \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 IB. Transl Lung Cancer Res. 11(1):75-86.<\/p>\n<p><strong>2021<\/strong><br \/>\n1) Mathilakathu A, Borchert S, Wessolly M, Mairinger E, Beckert H, Steinborn J, Hager T, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Schmid KW, Walter RFH, Brcic L, Mairinger FD (2021): \u062a\u0644\u0639\u0628 \u0627\u0644\u0645\u0633\u0627\u0631\u0627\u062a \u0627\u0644\u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0625\u0634\u0627\u0631\u0629 \u0627\u0644\u0645\u064a\u062a\u0648\u062c\u064a\u0646\u060c \u0648\u062a\u0646\u0638\u064a\u0645 \u0623\u064a\u0636 \u0627\u0644\u0637\u0627\u0642\u0629\u060c \u0648\u0627\u0644\u062a\u0648\u0633\u0637 \u0641\u064a \u0645\u0646\u0627\u0639\u064a\u0629 \u0627\u0644\u0648\u0631\u0645 \u0623\u062f\u0648\u0627\u0631\u064b\u0627 \u0623\u0633\u0627\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0627\u0644\u062e\u0644\u0648\u064a\u0629 \u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a\u0629 \u0627\u0644\u062e\u0628\u064a\u062b\u0629 \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0627\u0644\u0628\u0644\u0627\u062a\u064a\u0646: \u062f\u0631\u0627\u0633\u0629 \u0627\u0633\u062a\u0639\u0627\u062f\u064a\u0629. Transl Lung Cancer Res 10(7):3030-3042.<\/p>\n<p>2) Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, Waller CF, Thomas M, Eggert J, Schmid-Bindert G, Hoiczyk M, Christoph DC, Kimmich M, Deu\u00df B, Seifert S, Held S, Schuler M, Herold T, Breitenbuecher F, Eberhardt WEE (2021): \u062f\u0631\u0627\u0633\u0629 \u0639\u0634\u0648\u0627\u0626\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 II \u062a\u0642\u0627\u0631\u0646 \u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629 \u0648\u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0648\u0627\u0644\u062a\u062d\u0645\u0644 \u0644\u0646\u0638\u0627\u0645\u064a \u062c\u0631\u0639\u0627\u062a \u0645\u0646 \u0633\u064a\u0633\u0628\u0644\u0627\u062a\u064a\u0646 \u0648\u0628\u064a\u0645\u064a\u062a\u0631\u064a\u0643\u0633\u064a\u062f \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0623\u0648 \u0627\u0644\u0646\u0642\u064a\u0644\u064a. Ther Adv Med Oncol. 13:1758835921996506.<\/p>\n<p>3) Zeuschner P, H\u00f6lters S, St\u00f6ckle M, Seliger B, Mueller A, Bachmann HS, Gr\u00fcnwald V, Christoph DC, Stenzl A, Grimm MO, Br\u00fcning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-R\u00fcd I, Staehler M, Junker K (2021): \u062b\u0631\u0648\u0645\u0628\u0648\u0633\u0628\u0648\u0646\u062f\u064a\u0646-2 \u0648LDH \u0645\u0624\u0634\u0631\u0627\u062a \u062d\u064a\u0648\u064a\u0629 \u062a\u0646\u0628\u0624\u064a\u0629 \u0645\u062d\u062a\u0645\u0644\u0629 \u0644\u0644\u0639\u0644\u0627\u062c \u0628\u0625\u064a\u0641\u064a\u0631\u0648\u0644\u064a\u0645\u0648\u0633 \u0641\u064a \u0627\u0644\u062e\u0637 \u0627\u0644\u062b\u0627\u0646\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0643\u0644\u0648\u064a\u0629 \u0627\u0644\u0635\u0627\u0641\u064a \u0627\u0644\u0646\u0642\u064a\u0644\u064a (\u062f\u0631\u0627\u0633\u0629 MARC-2). Cancers (Basel) 13(11):2594.<br \/>\n4) Brcic L, Mathilakathu A, Walter RFH, Wessolly M, Mairinger E, Beckert H, Kreidt D, Steinborn J, Hager T, Christoph DC, Kollmeier J, Mairinger T, Wohlschlaeger J, Schmid KW, Borchert S, Mairinger FD (2021): \u064a\u0643\u0634\u0641 \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u062a\u0639\u0628\u064a\u0631 \u0627\u0644\u062c\u064a\u0646\u064a \u0627\u0644\u0631\u0642\u0645\u064a \u0644\u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u0638\u0647\u0627\u0631\u064a \u0648\u0627\u0644\u0633\u0627\u0631\u0643\u0648\u0645\u0627\u062a\u0648\u064a\u062f\u064a \u0639\u0646 \u0627\u062e\u062a\u0644\u0627\u0641\u0627\u062a \u0641\u064a \u0627\u0644\u0645\u0646\u0627\u0639\u064a\u0629. Cancers (Basel) 13(8):1761.<\/p>\n<p>5) Ferdinandus J, Metzenmacher M, Kessler L, Umutlu L, Aigner C, Karl KO, Gr\u00fcnwald V, Eberhardt W, Fendler WP, Herrmann K, Faehling M, Christoph DC (2021): \u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0623\u064a\u0636\u064a\u0629 \u0643\u0627\u0645\u0644\u0629 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0645\u0639 \u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0645\u0637\u0648\u0644\u0629 \u0644\u0639\u0644\u0627\u062c \u0645\u062b\u0628\u0637 \u0646\u0642\u0627\u0637 \u0627\u0644\u062a\u0641\u062a\u064a\u0634 \u0627\u0644\u0645\u0646\u0627\u0639\u064a. J Immunother Cancer 9(3):e002262.<\/p>\n<p>6) Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, G\u00fctz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F. (2021): \u0644\u0648\u0631\u0644\u0627\u062a\u064a\u0646\u064a\u0628 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a \u0644\u0640 ALK \u0623\u0648 ROS1 \u0628\u0639\u062f \u0639\u0644\u0627\u062c\u0627\u062a \u0633\u0627\u0628\u0642\u0629 \u0648\u062a\u0623\u062b\u064a\u0631 \u0627\u0644\u062a\u0631\u0627\u0641\u0642 \u0645\u0639 \u0637\u0641\u0631\u0627\u062a TP53: \u0646\u062a\u0627\u0626\u062c \u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0648\u0635\u0648\u0644 \u0627\u0644\u0645\u0628\u0643\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a. Ther Adv Med Oncol. 13:1758835920980558.<\/p>\n<p><strong>2020<\/strong><br \/>\n1)Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Sch\u00fctt P, Steger F, Br\u00fcckl WM, Christoph DC (2020). \u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0627\u0644\u062d\u0627\u0633\u0645 \u0641\u064a NSCLC \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0645\u0648\u0636\u0639\u064a\u064b\u0627: \u0628\u064a\u0627\u0646\u0627\u062a \u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0648\u0635\u0648\u0644 \u0627\u0644\u0645\u0628\u0643\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a (EAP). Data Brief 34:106556.<\/p>\n<p>2)Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Sch\u00fctt P, Steger F, Br\u00fcckl WM, Christoph DC (2020): \u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0627\u0644\u062d\u0627\u0633\u0645 \u0641\u064a \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0645\u0648\u0636\u0639\u064a\u064b\u0627 \u063a\u064a\u0631 \u0627\u0644\u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0633\u062a\u0626\u0635\u0627\u0644 (NSCLC): \u0628\u064a\u0627\u0646\u0627\u062a \u0648\u0627\u0642\u0639\u064a\u0629 \u0639\u0646 \u0627\u0644\u0628\u0642\u0627\u0621 \u0648\u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0645\u0646 \u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0648\u0635\u0648\u0644 \u0627\u0644\u0645\u0648\u0633\u0639 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a (EAP). Lung Cancer 150:114-122.<\/p>\n<p>3)Staehler M, St\u00f6ckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Br\u00fcning F, Goebell PJ, Augustin M, Roos F, Benz-R\u00fcd I, Marschner N, Gr\u00fcnwald V (2020): \u0625\u064a\u0641\u064a\u0631\u0648\u0644\u064a\u0645\u0648\u0633 \u0628\u0639\u062f \u0641\u0634\u0644 \u0639\u0644\u0627\u062c \u0648\u0627\u062d\u062f \u0633\u0627\u0628\u0642 \u0645\u0648\u062c\u0651\u0647 \u0644\u0640 VEGF \u0641\u064a \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0643\u0644\u0648\u064a\u0629 \u0627\u0644\u0646\u0642\u064a\u0644\u064a: \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0646\u0647\u0627\u0626\u064a\u0629 \u0644\u062a\u062c\u0631\u0628\u0629 MARC-2. Int J Cancer, 148(7):1685-1694.<\/p>\n<p>4)Jia Z, Wang Y, Cao L, Wang Y, Song Y, Yang X, Bing Z, Cao Z, Liu P, Zhang S, Chen Z, Huang M, Yu Y, Han-Zhang H, Song J, Christoph DC, Passaro A, Gridelli C, Hishida T, Liang N, Li S (2020): \u0627\u062e\u062a\u064a\u0627\u0631 \u0639\u0644\u0627\u062c \u0627\u0644\u062e\u0637 \u0627\u0644\u0623\u0648\u0644 \u0628\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0639\u0636\u0648\u064a\u0627\u062a (organoids) \u0644\u0645\u0631\u064a\u0636 \u0645\u0631\u062d\u0644\u0629 IA1 \u0645\u0639 EGFRm + TP53m \u0648\u062d\u062f\u0648\u062b \u0646\u0643\u0633 \u0646\u0642\u0627\u0626\u0644\u064a \u0645\u0628\u0643\u0631 \u0628\u0639\u062f \u0627\u0644\u062c\u0631\u0627\u062d\u0629 \u0627\u0644\u062c\u0630\u0631\u064a\u0629 \u0648\u0627\u0644\u0645\u062a\u0627\u0628\u0639\u0629. J Thorac Dis. 12(7):3764-3773.<\/p>\n<p>5)Ferdinandus J, Barbato F, Chodyla M, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Umutlu L, Herrmann K, Christoph DC (2020): \u062a\u0642\u064a\u064a\u0645 \u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0627\u0644\u062d\u062c\u0645\u064a\u0651\u0629 \u0628\u0627\u0644\u062a\u0635\u0648\u064a\u0631 \u0627\u0644\u0645\u0642\u0637\u0639\u064a \u0628\u0627\u0644\u0625\u0635\u062f\u0627\u0631 \u0627\u0644\u0628\u0648\u0632\u064a\u062a\u0631\u0648\u0646\u064a (PET) \u064a\u062a\u0641\u0648\u0642 \u0639\u0644\u0649 \u0627\u0644\u0645\u0639\u0627\u064a\u064a\u0631 \u0627\u0644\u062a\u0642\u0644\u064a\u062f\u064a\u0629 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u062a\u0644\u0642\u0648\u0646 \u062c\u0631\u0639\u0627\u062a \u0639\u0627\u0644\u064a\u0629 \u0645\u0646 \u0628\u064a\u0645\u0628\u0631\u0648\u0644\u064a\u0632\u0648\u0645\u0627\u0628 \u0644\u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062e\u0628\u064a\u062b. J Nucl Med., 62(2):191-194.<\/p>\n<p><strong>2019<\/strong><br \/>\n1)Walter RFH, Sydow SR, Berg E, Kollmeier J, Christoph DC, Christoph S, Eberhardt WEE, Mairinger T, Wohlschlaeger J, Schmid KW, Mairinger FD (2019): \u062d\u0633\u0627\u0633\u064a\u0629 \u0628\u0648\u0631\u062a\u064a\u0632\u0648\u0645\u064a\u0628 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0627\u0644\u0646\u0633\u064a\u062c\u060c \u0648\u0627\u0644\u062a\u0639\u0628\u064a\u0631 \u0627\u0644\u0645\u0631\u062a\u0641\u0639 \u0644\u0644\u0628\u0631\u0648\u062a\u064a\u0627\u0632\u0648\u0645 20S \u064a\u0633\u062a\u0628\u0639\u062f \u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0627\u0644\u062c\u064a\u062f\u0629 \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0627\u0644\u062e\u0628\u064a\u062b. Cancer Manag Res. 11:8711-8720.<\/p>\n<p>2)Krefting F, Basara N, Sch\u00fctte W, Sp\u00e4th-Schwalbed E, Alt J, Thiel S, Kimmich G, Fischer JR, Kurz S, Griesinger F, Christoph DC (2019): \u062e\u0628\u0631\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0641\u064a \u0639\u0644\u0627\u062c \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u0646\u0627\u0639\u064a: \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629 \u0648\u0627\u0644\u0633\u0645\u0651\u064a\u0629 \u0644\u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0631\u062d\u064a\u0645 \u0644\u0646\u064a\u0641\u0648\u0644\u0648\u0645\u0627\u0628 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062d\u0631\u0634\u0641\u064a \u0627\u0644\u0645\u062a\u0642\u062f\u0645. J Cancer Res Clin Oncol. 42(5):243-255.<\/p>\n<p>3Walter RFH, Vollbrecht C, Werner R, Borchert S, Schmeller J, Mairinger E, Herold T, Streubel A, Christoph DC\u200e, Mairinger T, Schmid KW, Wohlschl\u00e4ger J, Hager T, Mairinger F (2019): \u062a\u0624\u062b\u0631 \u0622\u0644\u064a\u0627\u062a \u0627\u0644\u0647\u0631\u0648\u0628 \u0627\u0644\u0645\u0639\u0627\u0644\u064e\u062c\u0629 \u0639\u0628\u0631 \u062a\u063a\u064a\u0651\u0631 \u0634\u0637\u0631 \u0627\u0644\u0628\u0631\u0648\u062a\u064a\u0627\u0632\u0648\u0645 \u0644\u0644\u062d\u0648\u0627\u062a\u0645 \u0641\u064a \u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0627\u0644\u0645\u0646\u0627\u0639\u064a\u0629 \u0641\u064a \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0639\u0635\u0628\u064a\u0629 \u0627\u0644\u0635\u0645\u0651\u0627\u0648\u064a\u0629 \u0627\u0644\u0631\u0626\u0648\u064a\u0629. Technol Cancer Res T, 17: 1533033818818418.<\/p>\n<p>4)Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Herold T, Christoph DC, Walter RFH, Eberhardt WEE, Pl\u00f6nes T, Wohlschlaeger J, Aigner C, Schmid KW, Mairinger FD (2019): \u064a\u0634\u064a\u0631 \u062a\u0648\u0635\u064a\u0641 \u0627\u0644\u062a\u0639\u0628\u064a\u0631 \u0627\u0644\u062c\u064a\u0646\u064a \u0644\u0645\u0633\u0627\u0631 \u0625\u0635\u0644\u0627\u062d \u0625\u0639\u0627\u062f\u0629 \u0627\u0644\u062a\u0631\u0643\u064a\u0628 \u0627\u0644\u0645\u062a\u0645\u0627\u062b\u0644 \u0625\u0644\u0649 \u0642\u0627\u0628\u0644\u064a\u0629 \u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0644\u0639\u0644\u0627\u062c \u0623\u0648\u0644\u0627\u0628\u0627\u0631\u064a\u0628 \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0627\u0644\u062e\u0628\u064a\u062b \u0641\u064a \u0627\u0644\u0645\u062e\u062a\u0628\u0631. BMC Cancer 19(1):108.<\/p>\n<p><strong>2018<\/strong><br \/>\n1)Stratmann JA, Michels S, Hornetz S, Christoph DC, Sackmann S, Spengler W, Bischoff H, Sch\u00e4fer M, Alt J, M\u00fcller A, Laack E, Kimmich M, Griesinger F, Sebastian M (2018): \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629 \u0648\u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0644\u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0648\u0635\u0648\u0644 \u0627\u0644\u0645\u0648\u0633\u0639 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0644\u0623\u0648\u0633\u064a\u0645\u064a\u0631\u062a\u064a\u0646\u064a\u0628 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a \u0644\u0640 T790M. J Cancer Res Clin Oncol. 144(12):2457-2463.<\/p>\n<p>2)Oezkan F, Herold T, Darwiche K, Eberhardt WEE, Worm K, Christoph DC, Wiesweg M, Freitag L, Schmid KW, Theegarten D, Hager T, Koenig MJ, He K, Taube C, Schuler M, Breitenbuecher F. (2018): \u0643\u0634\u0641 \u0633\u0631\u064a\u0639 \u0648\u0639\u0627\u0644\u064a \u0627\u0644\u062d\u0633\u0627\u0633\u064a\u0629 \u0644\u0644\u0637\u0641\u0631\u0627\u062a \u0627\u0644\u0645\u062d\u0631\u0651\u0650\u0643\u0629 \u0630\u0627\u062a \u0627\u0644\u0635\u0644\u0629 \u0627\u0644\u0639\u0644\u0627\u062c\u064a\u0629 \u0641\u064a \u0639\u064a\u0646\u0627\u062a EBUS-TBNA \u0645\u0646 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u063a\u062f\u0629 \u0627\u0644\u0631\u0626\u0648\u064a. Clin Lung Cancer. 19(6):e879-e884.<\/p>\n<p>3)Walter RFH, Werner R, Wessolly M, Mairinger E, Borchert S, Schmeller J, Kollmeier J, Mairinger T, Hager T, Bankfalvi A, Christoph DC, Eberhardt WEE, Pl\u00f6nes T, Aigner C, Schmid KW, Wohlschlaeger J, Mairinger FD (2018): \u062a\u062b\u0628\u064a\u0637 MDM2 \u0639\u0628\u0631 Nutlin-3A: \u0646\u0647\u062c \u0639\u0644\u0627\u062c\u064a \u0645\u062d\u062a\u0645\u0644 \u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a\u0629 \u0645\u0639 \u062a\u0639\u0637\u064a\u0644 P53 \u0645\u0646 \u0627\u0644\u0646\u0645\u0637 \u0627\u0644\u0628\u0631\u064a \u0627\u0644\u0645\u062d\u0631\u0651\u064e\u0636 \u0628\u0648\u0627\u0633\u0637\u0629 MDM2. J Oncol. 2018:1986982.<\/p>\n<p>4)Mairinger FD, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Pl\u00f6nes T, Wohlschlaeger J, Jasani B, Schmid KW, Bankfalvi A (2018): \u064a\u0631\u062a\u0628\u0637 \u062a\u0639\u0628\u064a\u0631 \u0627\u0644\u0645\u064a\u062a\u0627\u0644\u0648\u062b\u064a\u0648\u0646\u064a\u0646 \u0627\u0644\u0642\u0627\u0628\u0644 \u0644\u0644\u0643\u0634\u0641 \u0645\u0646\u0627\u0639\u064a\u064b\u0627 \u0641\u064a \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a\u0629 \u0627\u0644\u062e\u0628\u064a\u062b\u0629 \u0628\u0642\u0648\u0629 \u0628\u0627\u0644\u0641\u0634\u0644 \u0627\u0644\u0645\u0628\u0643\u0631 \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0627\u0644\u0628\u0644\u0627\u062a\u064a\u0646. Oncotarget. 9(32):22254-22268.<\/p>\n<p><strong>2017<\/strong><br \/>\n1)Peters S, Gettinger S, Johnson ML, J\u00e4nne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Fr\u00fch M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E (2017): \u062a\u062c\u0631\u0628\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 II \u0644\u0623\u062a\u064a\u0632\u0648\u0644\u064a\u0632\u0648\u0645\u0627\u0628 \u0643\u0639\u0644\u0627\u062c \u062e\u0637 \u0623\u0648\u0644 \u0623\u0648 \u0644\u0627\u062d\u0642 \u0644\u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0627\u0644\u0645\u062e\u062a\u0627\u0631 \u0648\u0641\u0642 \u062a\u0639\u0628\u064a\u0631 PD-L1 (BIRCH). J Clin Oncol. 35(24):2781-2789.<\/p>\n<p>2)Welter S, Arfanis E, Christoph D, Hager T, Roesel C, Aigner C, Weinreich G, Theegarten D (2017): \u0623\u0646\u0645\u0627\u0637 \u0646\u0645\u0648 \u0627\u0644\u0646\u0642\u0627\u0626\u0644 \u0627\u0644\u0631\u0626\u0648\u064a\u0629: \u0647\u0644 \u064a\u0646\u0628\u063a\u064a \u062a\u0639\u062f\u064a\u0644 \u062a\u0642\u0646\u064a\u0627\u062a \u0627\u0644\u0627\u0633\u062a\u0626\u0635\u0627\u0644 \u0648\u0641\u0642 \u0627\u0644\u0646\u0633\u064a\u062c \u0627\u0644\u0623\u0648\u0644\u064a \u0648\u0627\u0644\u062d\u062c\u0645\u061f Eur J Cardiothorac Surg. 52(1):39-46.<\/p>\n<p>3)Mairinger FD, Werner R, Flom E, Schmeller J, Borchert S, Wessolly M, Wohlschlaeger J, Hager T, Mairinger T, Kollmeier J, Christoph DC, Schmid KW, Walter RFH (2017): \u062a\u0646\u0638\u064a\u0645 miRNA \u0645\u0647\u0645 \u0644\u0625\u0635\u0644\u0627\u062d \u0623\u0636\u0631\u0627\u0631 DNA \u0648\u0627\u0644\u062a\u0639\u0631\u0651\u0641 \u0639\u0644\u064a\u0647\u0627 \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0627\u0644\u062e\u0628\u064a\u062b. Virchows Arch. 470(6):627-637.<\/p>\n<p>4)Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH (2017): \u0646\u0645\u0637 \u062d\u0645\u0636 \u0627\u0644\u0641\u0648\u0644\u064a\u0643 (FAP) \u0645\u0624\u0634\u0631 \u062d\u064a\u0648\u064a \u0645\u062a\u0641\u0648\u0642 \u0644\u0644\u062a\u0646\u0628\u0624 \u0628\u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0628\u064a\u0645\u064a\u062a\u0631\u064a\u0643\u0633\u064a\u062f \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0627\u0644\u062e\u0628\u064a\u062b. Oncotarget. 8(23):37502-37510.<\/p>\n<p>5)Wiesweg M, Eberhardt WE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, K\u00fchl H, Stuschke M, Schmid KW, Schuler M (2017): \u0627\u0646\u062a\u0634\u0627\u0631 \u0645\u0631\u062a\u0641\u0639 \u0644\u0637\u0641\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0645\u0631\u0627\u0641\u0642\u0629 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0645\u062d\u062f\u062f\u064a\u0646 \u0627\u0633\u062a\u0628\u0627\u0642\u064a\u064b\u0627 \u0628\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0646\u0642\u064a\u0644\u064a \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a \u0644\u0640 ROS1. J Thorac Oncol. 12 (1):54-64.<\/p>\n<p><strong>2016<\/strong><br \/>\n1)Metzenmacher M &#038; Christoph DC (2016): \u0641\u0639\u0627\u0644\u064a\u0629 \u0648\u0633\u0644\u0627\u0645\u0629 \u0646\u064a\u0641\u0648\u0644\u0648\u0645\u0627\u0628 \u0628\u0627\u0644\u0627\u0634\u062a\u0631\u0627\u0643 \u0645\u0639 \u0627\u0644\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0642\u064a\u0627\u0633\u064a\u0629 \u0643\u0639\u0644\u0627\u062c \u062e\u0637 \u0623\u0648\u0644 \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645. J Thorac Dis. 8 (10), E1254-E1256.<\/p>\n<p>2)Walter RF, Werner R, Vollbrecht C, Hager T, Flom E, Christoph DC, Schmeller J, Schmid KW, Wohlschlaeger J, Mairinger FD (2016): \u062a\u0645 \u062a\u062d\u062f\u064a\u062f ACTB \u0648CDKN1B \u0648GAPDH \u0648GRB2 \u0648RHOA \u0648SDCBP \u0643\u062c\u064a\u0646\u0627\u062a \u0645\u0631\u062c\u0639\u064a\u0629 \u0641\u064a \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0639\u0635\u0628\u064a \u0627\u0644\u0635\u0645\u0651\u0627\u0648\u064a \u0639\u0628\u0631 \u062a\u0642\u0646\u064a\u0629 nCounter. PLoS One. 11 (11), e0165181.<\/p>\n<p>3)Walter RF, Vollbrecht C, Werner R, Mairinger T, Schmeller J, Flom E, Wohlschlaeger J, Barbetakis N, Paliouras D, Chatzinikolaou F, Adamidis V, Tsakiridis K, Zarogoulidis P, Trakada G, Christoph DC, Schmid KW, Mairinger FD (2016): \u064a\u0645\u0643\u0646 \u0623\u0646 \u064a\u0639\u0632\u0632 \u0641\u062d\u0635 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a\u0629 \u0644\u0644\u0627\u0639\u0628\u064a\u0646 \u0625\u0635\u0644\u0627\u062d \u0623\u0636\u0631\u0627\u0631 DNA \u0639\u0628\u0631 \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u062a\u0639\u0628\u064a\u0631 \u0627\u0644\u062c\u064a\u0646\u064a \u0627\u0644\u0631\u0642\u0645\u064a \u0627\u0644\u062a\u062f\u0628\u064a\u0631 \u0627\u0644\u0633\u0631\u064a\u0631\u064a \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u062a\u0644\u0642\u0648\u0646 \u0639\u0644\u0627\u062c\u064b\u0627 \u0643\u064a\u0645\u064a\u0627\u0626\u064a\u064b\u0627 \u0642\u0627\u0626\u0645\u064b\u0627 \u0639\u0644\u0649 \u0627\u0644\u0628\u0644\u0627\u062a\u064a\u0646. J Cancer 7(13):1915-1925.<\/p>\n<p>4)Walter RF, Mairinger FD, Werner R, Vollbrecht C, Hager T, Schmid KW, Wohlschlaeger J, Christoph DC (2016): \u062a\u062e\u062a\u0644\u0641 \u0623\u0646\u0645\u0627\u0637 \u0623\u064a\u0636 \u062d\u0645\u0636 \u0627\u0644\u0641\u0648\u0644\u064a\u0643 \u0648\u0625\u0635\u0644\u0627\u062d DNA \u0628\u064a\u0646 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0639\u0635\u0628\u064a\u0629 \u0627\u0644\u0635\u0645\u0651\u0627\u0648\u064a\u0629 \u0648\u062a\u0631\u062a\u0628\u0637 \u0628\u0623\u0646\u0645\u0627\u0637 \u0641\u0631\u0639\u064a\u0629 \u0639\u062f\u0648\u0627\u0646\u064a\u0629 \u0648\u0645\u0642\u0627\u0648\u0645\u0629 \u0644\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c. Oncotarget 7(15):20166-79.<\/p>\n<p>5)Walter RF, Vollbrecht C, Werner R, Wohlschlaeger J, Christoph DC, Kurt Werner S, Mairinger FD (2016): \u062a\u064f\u0646\u0638\u0651\u064e\u0645 microRNAs \u0628\u0634\u0643\u0644 \u062a\u0641\u0627\u0636\u0644\u064a \u0628\u064a\u0646 \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0627\u0644\u062e\u0628\u064a\u062b \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a \u0644\u0640 MDM2 \u0648\u0627\u0644\u0633\u0644\u0628\u064a \u0644\u0647. Oncotarget. 7(14):18713-18721.<\/p>\n<p>6)Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D. (2016): \u0633\u064a\u0633\u0628\u0644\u0627\u062a\u064a\u0646 \u0641\u064a \u0627\u0644\u0639\u0635\u0631 \u0627\u0644\u062d\u062f\u064a\u062b: \u0627\u0644\u0639\u0645\u0648\u062f \u0627\u0644\u0641\u0642\u0631\u064a \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0643\u062e\u0637 \u0623\u0648\u0644 \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627. Cancer Treat Rev 44:42-50.<\/p>\n<p><strong>2015<\/strong><br \/>\n7)Vollbrecht C, Werner R, Walter RF, Christoph DC, Heukamp LC, Peifer M, Hirsch B, Burbat L, Mairinger T, Kurt Werner S, Wohlschlaeger J, Mairinger FD (2015): \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u0637\u0641\u0631\u0627\u062a \u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0631\u0626\u0629 \u0630\u0627\u062a \u0627\u0644\u0633\u0645\u0627\u062a \u0627\u0644\u0639\u0635\u0628\u064a\u0629 \u0627\u0644\u0635\u0645\u0651\u0627\u0648\u064a\u0629 \u0628\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u062a\u0633\u0644\u0633\u0644 \u0627\u0644\u0645\u0633\u062a\u0647\u062f\u0641 \u0627\u0644\u0645\u062a\u0648\u0627\u0632\u064a \u0648\u0627\u0633\u0639 \u0627\u0644\u0646\u0637\u0627\u0642: \u0645\u0642\u0627\u0631\u0646\u0629 \u0644\u0645\u062c\u0645\u0648\u0639\u0629 \u0623\u0648\u0631\u0627\u0645 \u0645\u064f\u0647\u0645\u064e\u0644\u0629. Br J Cancer 113(12):1704-1711.<\/p>\n<p>8)Oezkan F, Khan AM, Hager T, Freitag L, Christoph D, Darwiche K (2015): OSNA: \u0627\u062e\u062a\u0628\u0627\u0631 \u062c\u0632\u064a\u0626\u064a \u0633\u0631\u064a\u0639 \u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u062a\u0631\u0643\u064a\u0632 CK19 mRNA \u0644\u062a\u0642\u064a\u064a\u0645 \u0639\u064a\u0646\u0627\u062a EBUS-TBNA \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629. Clin Lung Cancer. 17(3):198-204.<\/p>\n<p>9)Walter RF, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Christoph DC, Zarogoulidis K, Schmid KW, Zarogoulidis P, Wohlschlaeger (2015): \u062a\u0645 \u062a\u062d\u062f\u064a\u062f \u062a\u0639\u0628\u064a\u0631 mRNA \u0644\u0640 SOX4 \u0648SOX11 \u0648PAX6 \u0643\u0648\u0627\u0633\u0645 (\u0625\u0646\u0630\u0627\u0631\u064a) \u0644\u0639\u062f\u0648\u0627\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0639\u0635\u0628\u064a\u0629 \u0627\u0644\u0635\u0645\u0651\u0627\u0648\u064a\u0629 \u0641\u064a \u0627\u0644\u0631\u0626\u0629 \u0628\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u062a\u0639\u0628\u064a\u0631 \u0645\u0646 \u0627\u0644\u062c\u064a\u0644 \u0627\u0644\u062a\u0627\u0644\u064a (NanoString). J. Future Oncol. 11(7):1027-1036.<\/p>\n<p>10)Reis H, Herold T, Ting S, Worm K, Huber U, Christoph DC, Eberhardt WE, Kostbade K, Kasper S, Stamatis G, Welter S, Darwiche K, Karpf-Wissel R, Theegarten D, Schmid KW, Schuler M, Wiesweg M (2015): \u064a\u062d\u062f\u062f \u062a\u0639\u0628\u064a\u0631 HER2 \u0648\u0648\u0627\u0633\u0645\u0627\u062a \u062a\u0646\u0634\u064a\u0637 \u0645\u0633\u0627\u0631 \u0641\u0648\u0633\u0641\u0648\u064a\u0646\u0648\u0632\u064a\u062a\u064a\u062f-3-\u0643\u064a\u0646\u0627\u0632 \u0645\u062c\u0645\u0648\u0639\u0629 \u0641\u0631\u0639\u064a\u0629 \u0645\u0648\u0627\u062a\u064a\u0629 \u0645\u0646 \u0627\u0644\u0633\u0631\u0637\u0627\u0646\u0627\u062a \u0627\u0644\u063a\u062f\u064a\u0629 \u0627\u0644\u0631\u0626\u0648\u064a\u0629 \u0627\u0644\u0646\u0642\u064a\u0644\u064a\u0629. Lung Cancer 88(1):34-41.<\/p>\n<p>11)Walter RF, Mairinger FD, Ting S, Vollbrecht C, Mairinger T, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J (2015): \u064a\u064f\u0639\u062f MDM2 \u0639\u0627\u0645\u0644\u064b\u0627 \u0625\u0646\u0630\u0627\u0631\u064a\u064b\u0627 \u0648\u062a\u0646\u0628\u0624\u064a\u064b\u0627 \u0645\u0647\u0645\u064b\u0627 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0628\u0644\u0627\u062a\u064a\u0646-\u0628\u064a\u0645\u064a\u062a\u0631\u064a\u0643\u0633\u064a\u062f \u0641\u064a \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a\u0629 \u0627\u0644\u062e\u0628\u064a\u062b\u0629\u060c \u0648\u064a\u0628\u062f\u0648 \u0623\u0646 \u0627\u062e\u062a\u0644\u0627\u0644 \u062a\u0646\u0638\u064a\u0645 P14\/ARF (\u0627\u0644\u0645\u0634\u0641\u0651\u064e\u0631 \u0628\u0648\u0627\u0633\u0637\u0629 CDKN2A) \u064a\u0633\u0627\u0647\u0645 \u0641\u064a \u062a\u0639\u0637\u064a\u0644 P53 \u0627\u0644\u0645\u062f\u0641\u0648\u0639 \u0628\u0640 MDM2. Br J Cancer 112(5):883-890.<\/p>\n<p>12)Walter RF, Werner R, Ting S, Vollbrecht C, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J, Mairinger FD (2015): \u062a\u062d\u062f\u064a\u062f \u0627\u062e\u062a\u0644\u0627\u0644 \u062a\u0646\u0638\u064a\u0645 \u0627\u0644\u0627\u0633\u062a\u0645\u0627\u062a\u0629 \u0648\u062f\u0648\u0631\u0629 \u0627\u0644\u062e\u0644\u064a\u0629 \u0641\u064a \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0639\u0635\u0628\u064a\u0629 \u0627\u0644\u0635\u0645\u0651\u0627\u0648\u064a\u0629 \u0641\u064a \u0627\u0644\u0631\u0626\u0629 \u0639\u0628\u0631 \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u062a\u0639\u0628\u064a\u0631 NanoString nCounter. Oncotarget. 6(28):24690-24698.<\/p>\n<p><strong>2014<\/strong><br \/>\n1)Mairinger FD, Walter RF, Theegarten D, Hager T, Vollbrecht C, Christoph DC, Worm K, Ting S, Werner R, Stamatis G, Mairinger T, Baba H, Zarogoulidis K, Huang H, Li Q, Tsakiridis K, Zarogoulidis P, Kurt Werner S &#038; Wohlschlaeger J (2014): \u064a\u0643\u0634\u0641 \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u062a\u0639\u0628\u064a\u0631 \u0627\u0644\u062c\u064a\u0646\u064a \u0644\u0644\u0648\u062d\u062f\u0629 \u0627\u0644\u0641\u0631\u0639\u064a\u0629 PSMB4 \u0645\u0646 \u0627\u0644\u0628\u0631\u0648\u062a\u064a\u0627\u0632\u0648\u0645 26S \u0639\u0646 \u0632\u064a\u0627\u062f\u0629 \u062a\u0646\u0638\u064a\u0645 \u0645\u0644\u062d\u0648\u0638\u0629 \u0648\u062a\u0639\u0628\u064a\u0631 \u0645\u062e\u062a\u0644\u0641 \u0648\u0627\u0631\u062a\u0628\u0627\u0637 \u0628\u0627\u0644\u062a\u0643\u0627\u062b\u0631 \u0641\u064a \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0639\u0635\u0628\u064a\u0629 \u0627\u0644\u0635\u0645\u0651\u0627\u0648\u064a\u0629 \u0644\u062f\u0649 \u0627\u0644\u0628\u0634\u0631. J Cancer 5(8):646-654.<\/p>\n<p>2)Darwiche K, \u00d6zkan F, Ting S, Johnen G, Br\u00fcning T, Soltermann A, Huber LC, Christoph DC, Freitag L &#038; Franzen D (2014): \u0645\u0624\u0634\u0631\u0627\u062a \u062d\u064a\u0648\u064a\u0629 \u0642\u0628\u0644 \u0627\u0644\u0639\u0644\u0627\u062c \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0645\u0639 \u0625\u064a\u0644\u0627\u0621 \u0627\u0647\u062a\u0645\u0627\u0645 \u062e\u0627\u0635 \u0644\u0625\u062c\u0631\u0627\u0621\u0627\u062a \u062a\u0646\u0638\u064a\u0631 \u0627\u0644\u0642\u0635\u0628\u0627\u062a [Role of pretherapeutic biomarkers in lung cancer with special regards to bronchoscopic procedures]. Pneumologie 68 (11), 719-726.<\/p>\n<p>3)Mairinger FD, Walter RF, Werner R, Christoph DC, Ting S, Vollbrecht C, Zarogoulidis K, Huang H, Li Q, Schmid KW, Wohlschlaeger J &#038; Zarogoulidis P (2014): \u064a\u062e\u062a\u0644\u0641 \u062a\u0646\u0634\u064a\u0637 \u062a\u0643\u0648\u0651\u0646 \u0627\u0644\u0623\u0648\u0639\u064a\u0629 \u0628\u0634\u0643\u0644 \u0643\u0628\u064a\u0631 \u0628\u064a\u0646 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0633\u0631\u0637\u0627\u0648\u064a\u0629 \u0627\u0644\u0631\u0626\u0648\u064a\u0629 \u0648\u0627\u0644\u0633\u0631\u0637\u0627\u0646\u0627\u062a \u0627\u0644\u0639\u0635\u0628\u064a\u0629 \u0627\u0644\u0635\u0645\u0651\u0627\u0648\u064a\u0629\u060c \u0648\u0647\u0648 \u062d\u0627\u0633\u0645 \u0644\u062a\u0643\u0648\u0651\u0646 \u0627\u0644\u0648\u0631\u0645 \u0627\u0644\u0633\u0631\u0637\u0627\u0648\u064a. J Cancer 5 (6), 465-471.<\/p>\n<p>4)Mairinger FD, Walter RF, Ting S, Vollbrecht C, Kollmeier J, Griff S, Hager T, Mairinger T, Christoph DC, Theegarten D, Kurt Werner S &#038; Wohlschlaeger J (2014): \u064a\u0631\u062a\u0628\u0637 \u062a\u0639\u0628\u064a\u0631 \u0628\u0631\u0648\u062a\u064a\u0646 Mdm2 \u0628\u0642\u0648\u0629 \u0628\u0627\u0644\u0628\u0642\u0627\u0621 \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0627\u0644\u062e\u0628\u064a\u062b. Future Oncol. 10 (6), 995-1005.<\/p>\n<p>5)Christoph DC, Reyna-Asuncion B, Hassan B, Tran C, Maltzman JD, O\u2019Shannessy DJ, Gauler TC, Wohlschlaeger J, Schuler M, Eberhardt WE &#038; Hirsch FRH (2014). \u062a\u0642\u064a\u064a\u0645 \u062a\u0639\u0628\u064a\u0631 \u0645\u0633\u062a\u0642\u0628\u0644 \u0627\u0644\u0641\u0648\u0644\u0627\u062a \u0623\u0644\u0641\u0627 \u0648\u0645\u0633\u062a\u0642\u0628\u0644 \u0639\u0627\u0645\u0644 \u0646\u0645\u0648 \u0627\u0644\u0628\u0634\u0631\u0629 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0639\u0627\u0644\u062c\u064a\u0646 \u0628\u0628\u064a\u0645\u064a\u062a\u0631\u064a\u0643\u0633\u064a\u062f. Clin Lung Cancer 15 (5), 320-330.<\/p>\n<p>6)Mairinger FD, Ting S, Werner R, Walter RF, Hager T, Vollbrecht C, Christoph D, Worm K, Mairinger T, Sheu-Grabellus SY, Theegarten D, Schmid KW &#038; Wohlschlaeger J (2014): \u062a\u0645\u064a\u0651\u0632 \u0623\u0646\u0645\u0627\u0637 \u062a\u0639\u0628\u064a\u0631 micro-RNA \u0627\u0644\u0645\u062e\u062a\u0644\u0641\u0629 \u0627\u0644\u0623\u0646\u0645\u0627\u0637 \u0627\u0644\u0641\u0631\u0639\u064a\u0629 \u0644\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0639\u0635\u0628\u064a\u0629 \u0627\u0644\u0635\u0645\u0651\u0627\u0648\u064a\u0629 \u0641\u064a \u0627\u0644\u0631\u0626\u0629: \u0646\u062a\u0627\u0626\u062c \u062f\u0631\u0627\u0633\u0629 \u062a\u0648\u0635\u064a\u0641. Mod Pathol. 27 (12), 1623-1640.<\/p>\n<p>7Nensa F, Stattaus J, Morgan B, Horsfield MA, Soria JC, Besse B, Gounant V, Khalil A, Seng K, Fischer B, Krissel H, Laurent D, Christoph D, Eberhardt WE &#038; Gauler TC (2014): \u0645\u0639\u0644\u0645\u0627\u062a \u0627\u0644\u062a\u0635\u0648\u064a\u0631 \u0628\u0627\u0644\u0631\u0646\u064a\u0646 \u0627\u0644\u0645\u063a\u0646\u0627\u0637\u064a\u0633\u064a \u0627\u0644\u0645\u0639\u0632\u0632 \u0628\u0627\u0644\u062a\u0628\u0627\u064a\u0646 \u0627\u0644\u062f\u064a\u0646\u0627\u0645\u064a\u0643\u064a \u0643\u0645\u0624\u0634\u0631\u0627\u062a \u062d\u064a\u0648\u064a\u0629 \u0644\u062a\u0623\u062b\u064a\u0631 \u0641\u0627\u062a\u0627\u0644\u0627\u0646\u064a\u0628 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627. Future Oncol. 10 (5), 823-333.<\/p>\n<p>8)Christoph DC &#038; Eberhardt WE (2014): \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u0647\u0627\u0632\u064a \u0644\u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0627\u0644\u062e\u0628\u064a\u062b: \u0639\u0648\u0627\u0645\u0644 \u062c\u062f\u064a\u062f\u0629 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u062a\u0628\u0639\u062b \u0627\u0644\u0623\u0645\u0644 \u0628\u062a\u062d\u0633\u064a\u0646\u0627\u062a \u0630\u0627\u062a \u0635\u0644\u0629. Curr Opin Oncol. 26 (2), 171-181.<\/p>\n<p><strong>2013<\/strong><br \/>\n1)Eberhardt WEE, Hoiczyk M &#038; Christoph DC (2013): \u0639\u0644\u0627\u062c \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629. TumorDiagn u Ther. 34 (8), 449-452.<\/p>\n<p>2)Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW &#038; Christoph DC (2013): ERCC1 \u0648MLH1 \u0648MSH2 \u0648MSH6 \u0648\u03b2III-tubulin: \u0628\u0631\u0648\u062a\u064a\u0646\u0627\u062a \u0645\u0642\u0627\u0648\u0645\u0629 \u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0627\u0644\u0628\u0644\u0627\u062a\u064a\u0646. Clin Lung Cancer 14 (5), 558-567.<\/p>\n<p>3)Gauler TC, Christoph DC, Fischer J, Frickhofen N, Huber R, Gonschorek C, Roth K, Giurescu M &#038; Eberhardt WEE (2013): \u062f\u0631\u0627\u0633\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 I \u0644\u0633\u0627\u063a\u0648\u0628\u064a\u0644\u0648\u0646 (ZK-EPO) \u0628\u0627\u0644\u0627\u0634\u062a\u0631\u0627\u0643 \u0645\u0639 \u0633\u064a\u0633\u0628\u0644\u0627\u062a\u064a\u0646 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0646\u0642\u064a\u0644\u064a \u063a\u064a\u0631 \u0627\u0644\u0645\u0639\u0627\u0644\u062c\u064a\u0646 \u0633\u0627\u0628\u0642\u064b\u0627 \u0628\u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a. Eur J Cancer 49 (11), 2461-2468.<\/p>\n<p>4)Christoph DC &#038; Reckamp KL (2013): \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u062f\u0627\u062e\u0644 \u0627\u0644\u0628\u0637\u064a\u0646 \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0633\u062d\u0627\u064a\u0627 \u0627\u0644\u0645\u0646\u062a\u0634\u0631 (leptomeningeal carcinomatosis) \u0627\u0644\u0646\u0627\u062c\u0645 \u0639\u0646 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u2013 \u0647\u0644 \u0647\u0648 \u062e\u064a\u0627\u0631 \u0639\u0644\u0627\u062c\u064a \u0645\u0645\u0643\u0646 \u0648\u0645\u0641\u064a\u062f\u061f J Thorac Oncol. 8 (5), 523-524.<\/p>\n<p>5)Welter S, Schwan A, Cheufou D, Darwiche K, Christoph D, Eberhardt W, Weinreich G &#038; Stamatis G. (2013): \u062a\u063a\u064a\u0651\u0631\u0627\u062a \u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u0623\u0645\u062f \u0641\u064a \u062c\u0648\u062f\u0629 \u0627\u0644\u062d\u064a\u0627\u0629: \u062a\u0642\u064a\u064a\u0645 \u0627\u0633\u062a\u0628\u0627\u0642\u064a \u0628\u0639\u062f \u0627\u0633\u062a\u0626\u0635\u0627\u0644 \u0646\u0642\u0627\u0626\u0644 \u0631\u0626\u0648\u064a\u0629 \u0645\u0641\u062a\u0648\u062d. Ann Thorac Surg. 95 (3), 1006-1011.<\/p>\n<p>6)Christoph DC, Reyna Asuncion B, Hassan B, Tran C, Maltzman JD, O\u2019Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WEE &#038; Hirsch FR (2013): \u0623\u0647\u0645\u064a\u0629 \u062a\u0639\u0628\u064a\u0631 \u0645\u0633\u062a\u0642\u0628\u0644 \u0627\u0644\u0641\u0648\u0644\u0627\u062a \u0623\u0644\u0641\u0627 \u0648\u062b\u064a\u0645\u064a\u062f\u064a\u0644\u0627\u062a \u0633\u064a\u0646\u062b\u0627\u0632 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0639\u0627\u0644\u062c\u064a\u0646 \u0628\u0628\u064a\u0645\u064a\u062a\u0631\u064a\u0643\u0633\u064a\u062f. J Thorac Oncol, 9 (1), 19-30.<\/p>\n<p><strong>2012<\/strong><br \/>\n7) Christoph DC, Reyna Asuncion B, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp C, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): \u064a\u0631\u062a\u0628\u0637 \u062a\u0639\u0628\u064a\u0631 \u0625\u0646\u0632\u064a\u0645 Folylpoly-glutamate synthetase \u0628\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0627\u0644\u0648\u0631\u0645 \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0628\u064a\u0645\u064a\u062a\u0631\u064a\u0643\u0633\u064a\u062f \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0627\u0644\u062e\u0628\u064a\u062b. J Thorac Oncol. 7 (9), 1440-1448.<\/p>\n<p>8)Christoph DC, Kasper S, Gauler TC, Loesch C, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Welter S, Stamatis G, Hirsch FR, Schuler M, Eberhardt WEE &#038; Wohlschlaeger J (2012): \u064a\u0631\u062a\u0628\u0637 \u062a\u0639\u0628\u064a\u0631 \u03b2V-tubulin \u0628\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0627\u0644\u062a\u0627\u0643\u0633\u0627\u0646 \u0641\u064a \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627. Br J Cancer. 107 (5), 823-830.<\/p>\n<p>9)Wynes MW, Konopa K, Singh S, Asuncion BR, Ranger-Moore J, Sternau A, Christoph DC, Dzidziuszko R, Jassem J &#038; Hirsch FR (2012). \u064a\u0631\u062a\u0628\u0637 \u062a\u0639\u0628\u064a\u0631 \u0628\u0631\u0648\u062a\u064a\u0646 \u062b\u064a\u0645\u064a\u062f\u064a\u0644\u0627\u062a \u0633\u064a\u0646\u062b\u0627\u0632 \u0628\u0648\u0627\u0633\u0637\u0629 IHC \u0648\u0639\u062f\u062f \u0646\u0633\u062e \u0627\u0644\u062c\u064a\u0646 \u0628\u0648\u0627\u0633\u0637\u0629 SISH \u0648\u064a\u064f\u0638\u0647\u0631 \u062a\u0628\u0627\u064a\u0646\u064b\u0627 \u0643\u0628\u064a\u0631\u064b\u0627 \u0641\u064a \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627. J Thorac Oncol. 7 (6), 982-992.<\/p>\n<p>10)Christoph DC, Hoffmann, A-C, Gauler TC, Reyna Asuncion B, Loewendick H, Peglow A, Hassan B, Tran C, Wynes MW, Schuler M, Eberhardt WE &#038; Hirsch FR (2012). \u0643\u0634\u0641 \u062e\u0644\u0627\u064a\u0627 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u062f\u0627\u0626\u0631\u0629 \u0630\u0627\u062a \u062a\u0641\u0627\u0639\u0644 \u0642\u0648\u064a \u0644\u062b\u064a\u0645\u064a\u062f\u064a\u0644\u0627\u062a \u0633\u064a\u0646\u062b\u0627\u0632 \u0641\u064a \u0627\u0644\u062f\u0645 \u0627\u0644\u0645\u062d\u064a\u0637\u064a \u0644\u0645\u0631\u064a\u0636 \u0628\u0633\u0631\u0637\u0627\u0646 \u063a\u062f\u064a \u0631\u0626\u0648\u064a \u0639\u0648\u0644\u062c \u0628\u0628\u064a\u0645\u064a\u062a\u0631\u064a\u0643\u0633\u064a\u062f. J Thorac Oncol. 7 (4), 766-767.<\/p>\n<p><strong>2011<\/strong><br \/>\n1)Christoph DC &#038; Schuler M (2011). \u0645\u062b\u0628\u0637\u0627\u062a Plk1 \u0641\u064a \u0627\u0644\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0623\u062d\u0627\u062f\u064a\u0629 \u0648\u0627\u0644\u0645\u0631\u0643\u0628\u0629: \u0627\u0633\u062a\u0631\u0627\u062a\u064a\u062c\u064a\u0629 \u062c\u062f\u064a\u062f\u0629 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u062e\u0628\u064a\u062b\u0629. Expert Rev. Anticancer Ther. 11 (7), 1117-1132.<\/p>\n<p>2)Christoph DC, Witkowski L, Stattaus J, Poettgen C, Keyvani C, Gauler TC, Schuler M &#038; Eberhardt WEE (2011). \u0646\u0643\u0633 \u0633\u062d\u0627\u0626\u064a \u0645\u062a\u0623\u062e\u0631 \u062c\u062f\u064b\u0627 \u0648\u0645\u0639\u0632\u0648\u0644 \u0644\u0633\u0631\u0637\u0627\u0646 \u063a\u062f\u064a \u0631\u0626\u0648\u064a \u0638\u0647\u0631 \u0639\u0644\u0649 \u0634\u0643\u0644 \u062e\u0631\u0641. Onkologie 34 (6), 316-320.<\/p>\n<p><strong>2009<\/strong><br \/>\n1)Christoph DC, Boese D, Johnson KT, Schlosser TW, Hunold P, Baba HA, Erbel R &#038; Philipp S (2009). \u0641\u0634\u0644 \u0642\u0644\u0628\u064a \u0648\u0625\u0635\u0627\u0628\u0629 \u0642\u0644\u0628\u064a\u0629 \u0643\u062a\u0638\u0627\u0647\u0631 \u0645\u0639\u0632\u0648\u0644 \u0644\u0634\u0643\u0644 \u0639\u0627\u0626\u0644\u064a \u0645\u0646 \u0627\u0644\u062f\u0627\u0621 \u0627\u0644\u0646\u0634\u0648\u0627\u0646\u064a \u0644\u0644\u062a\u0631\u0627\u0646\u0633\u062a\u064a\u0631\u064a\u062a\u064a\u0646 \u0646\u0627\u062a\u062c \u0639\u0646 \u0637\u0641\u0631\u0629 Val30Met \u062f\u0648\u0646 \u0639\u0644\u0627\u0645\u0627\u062a \u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0627\u0639\u062a\u0644\u0627\u0644 \u0627\u0644\u0623\u0639\u0635\u0627\u0628 \u0627\u0644\u0645\u062a\u0639\u062f\u062f. Circ Heart Fail. 2 (5), 512-515.<\/p>\n<p><strong>2004<\/strong><br \/>\n2)Keiper M, Stope MB, Szatkowski DC, B\u00f6hm A, Tysack K, vom Dorp F, Saur O, Oude Weernink PA, Evellin S, Jakobs KH &#038; Schmidt M. \u062a\u0646\u0634\u064a\u0637 Ras \u0648\u0643\u064a\u0646\u0627\u0632\u0627\u062a \u0627\u0644\u0625\u0634\u0627\u0631\u0629 \u0627\u0644\u0645\u0646\u0638\u0645\u0629 \u062e\u0627\u0631\u062c \u0627\u0644\u062e\u0644\u064a\u0629 \u0627\u0644\u0645\u0639\u062a\u0645\u062f\u0629 \u0639\u0644\u0649 Epac \u0648Ca2+ \u0628\u0648\u0627\u0633\u0637\u0629 \u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0645\u0642\u062a\u0631\u0646\u0629 \u0628\u0640 Gs (2004). J Biol Chem. 279 (45), 46497-46508.<\/p>\n<p>3)Stope MB, vom Dorp F, Szatkowski DC, B\u00f6hm A, Keiper M, Nolte J, Oude Weernink PA, Rosskopf D, Evellin S, Jakobs KH &#038; Schmidt M (2004). \u062a\u062d\u0641\u064a\u0632 \u0641\u0648\u0633\u0641\u0648\u0644\u064a\u0628\u0627\u0632 C-\u0625\u0628\u0633\u064a\u0644\u0648\u0646 \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0639\u0644\u0649 Rap2B \u0628\u0648\u0627\u0633\u0637\u0629 \u0645\u0633\u062a\u0642\u0628\u0644 \u0639\u0627\u0645\u0644 \u0646\u0645\u0648 \u0627\u0644\u0628\u0634\u0631\u0629 \u0628\u0648\u0633\u0627\u0637\u0629 \u0641\u0633\u0641\u0631\u0629 RasGRP3 \u0639\u0628\u0631 c-Src. Mol Cell Biol. 24 (11), 4664-4676.<\/p>\n<p><strong>\u0627\u0644\u0645\u0644\u062e\u0635\u0627\u062a \u0648\u0627\u0644\u0639\u0631\u0648\u0636 \u0627\u0644\u062a\u0642\u062f\u064a\u0645\u064a\u0629 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631\u0627\u062a:<\/strong><\/p>\n<p><strong>2024<\/strong><br \/>\n1) Shah R, Reck M, Grohe C, Christoph DC, Buchmeier EL, Saalfeld FC, Frost N, Kopp H-G, Faehling M, Griesinger F, Roeper J, Hoffknecht P, Kuon J, Luan J, Chesi P, Christopoulos P, Thomas M (2024): \u0641\u0639\u0627\u0644\u064a\u0629 \u0646\u064a\u0641\u0648\u0644\u0648\u0645\u0627\u0628\/\u0625\u064a\u0628\u064a\u0644\u064a\u0645\u0648\u0645\u0627\u0628 \u0643\u0639\u0644\u0627\u062c \u062e\u0637 \u0623\u0648\u0644 \u0644\u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0641\u064a \u0628\u064a\u0626\u0629 \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a\u0629. J Clin Oncol 42, 2024 (suppl 16; abstr 8085). \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0633\u0631\u064a\u0631\u064a (ASCO).<\/p>\n<p>2) Hautzel H, Metzenmacher M, B\u00f6l\u00fckbas S, Volmerig J, Nilius G, Kersting D, Moka D, Herrmann K, Christoph D (2024): \u0645\u0639\u0644\u0645\u0627\u062a \u062d\u062c\u0645 \u0627\u0644\u0648\u0631\u0645 MTV \u0648TLG \u0644\u0644\u062a\u0646\u0628\u0624 \u0628\u0627\u0644\u0628\u0642\u0627\u0621 \u062f\u0648\u0646 \u062a\u0642\u062f\u0645 \u0627\u0644\u0645\u0631\u0636 \u0648\u0627\u0644\u0628\u0642\u0627\u0621 \u0627\u0644\u0643\u0644\u064a \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062e\u0628\u064a\u062b \u063a\u064a\u0631 \u0627\u0644\u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0633\u062a\u0626\u0635\u0627\u0644 \u062a\u062d\u062a \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u0646\u0627\u0639\u064a \u0627\u0644\u0645\u0632\u062f\u0648\u062c \u0628\u0625\u064a\u0628\u064a\u0644\u064a\u0645\u0648\u0645\u0627\u0628 \u0648\u0646\u064a\u0641\u0648\u0644\u0648\u0645\u0627\u0628: \u0645\u0627 \u0627\u0644\u0630\u064a \u064a\u0645\u0643\u0646 \u0623\u0646 \u064a\u0642\u062f\u0645\u0647 FDG PET\/CT \u0627\u0644\u0623\u0633\u0627\u0633\u064a\u061f NuclearMedicine 63 (2), V06. \u0639\u0631\u0636 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a\u0629 \u0644\u0644\u0637\u0628 \u0627\u0644\u0646\u0648\u0648\u064a.<\/p>\n<p>3) Christoph D, Metzenmacher M, B\u00f6l\u00fckbas S, Volmerig J, Nilius G, Moka D, Hautzel H (2024): \u064a\u0643\u0634\u0641 PET-CT \u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0644\u0644\u0639\u0644\u0627\u062c \u0628\u0625\u064a\u0628\u064a\u0644\u064a\u0645\u0648\u0645\u0627\u0628 \u0648\u0646\u064a\u0641\u0648\u0644\u0648\u0645\u0627\u0628 \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062e\u0628\u064a\u062b \u0628\u0634\u0643\u0644 \u0623\u0641\u0636\u0644 \u0645\u0646 CT. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 47 (\u0627\u0644\u0645\u0644\u062d\u0642 1)\u060c P756. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u0633\u0627\u062f\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>4) Karthaus M, Christoph D, Lux MP, Hofheinz R-D, Jordan K (2024): \u062a\u0642\u064a\u064a\u0645 \u0641\u0627\u0626\u062f\u0629 NEPA (\u062a\u0631\u0643\u064a\u0628\u0629 \u062b\u0627\u0628\u062a\u0629 \u0645\u0646 Netupitant\/Palonosetron) \u0644\u0644\u0648\u0642\u0627\u064a\u0629 \u0645\u0646 \u0627\u0644\u063a\u062b\u064a\u0627\u0646 \u0648\u0627\u0644\u0642\u064a\u0621 \u0627\u0644\u0646\u0627\u062c\u0645\u064a\u0646 \u0639\u0646 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a (CINV) \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0630\u0648\u064a \u062e\u0637\u0631 \u0645\u0631\u062a\u0641\u0639 \u0644\u0644\u0642\u064a\u0621 \u0627\u0644\u0630\u064a\u0646 \u064a\u062a\u0644\u0642\u0648\u0646 \u0639\u0644\u0627\u062c\u064b\u0627 \u0643\u064a\u0645\u064a\u0627\u0626\u064a\u064b\u0627 \u0645\u062a\u0648\u0633\u0637 \u0627\u0644\u0625\u062d\u062f\u0627\u062b \u0644\u0644\u0642\u064a\u0621. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 47 (\u0627\u0644\u0645\u0644\u062d\u0642 1)\u060c P445. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u0633\u0627\u062f\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>5) Reitnauer L, Evers G, Christoph D, Br\u00fcckl W, Wiesweg M, Glanemann F, Webend\u00f6rfer M, Kropf-Sanchen C, Acker F, Sch\u00fctte W, Hoffknecht P, Kerkhoff A, Mohr M, Lenz G, Frost N, Overbeck T, Sebastian M, Bleckmann A (2024): \u0646\u0643\u0633 NSCLC \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0645\u0648\u0636\u0639\u064a\u064b\u0627 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0648\u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 \u0627\u0644\u062a\u0648\u0637\u064a\u062f\u064a \u2013 \u062a\u062d\u0644\u064a\u0644 \u0627\u0633\u062a\u0639\u0627\u062f\u064a \u0623\u0644\u0645\u0627\u0646\u064a \u0645\u062a\u0639\u062f\u062f \u0627\u0644\u0645\u0631\u0627\u0643\u0632. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 47 (\u0627\u0644\u0645\u0644\u062d\u0642 1)\u060c P947. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u0633\u0627\u062f\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>6) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph DC (2024): \u0625\u0646 \u0645\u0639\u0627\u0644\u062c\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u0647\u0627\u0632\u064a \u0643\u062e\u0637 \u0623\u0648\u0644 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0645\u0633\u0646\u064a\u0646 \u0623\u0645\u0631 \u0628\u0627\u0644\u063a \u0627\u0644\u0623\u0647\u0645\u064a\u0629. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 47 (\u0627\u0644\u0645\u0644\u062d\u0642 1)\u060c P755. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u0633\u0627\u062f\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p><strong>2023<\/strong><br \/>\n1) Christoph DCCC, Metzenmacher M, B\u00f6l\u00fckbas S, Volmerig4 J, Nilius G, Moka D, Hautzel H (2023): \u064a\u0643\u0634\u0641 PET-CT \u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0644\u0644\u0639\u0644\u0627\u062c \u0628\u0625\u064a\u0628\u064a\u0644\u064a\u0645\u0648\u0645\u0627\u0628 \u0648\u0646\u064a\u0641\u0648\u0644\u0648\u0645\u0627\u0628 \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062e\u0628\u064a\u062b \u0628\u0634\u0643\u0644 \u0623\u0641\u0636\u0644 \u0628\u0643\u062b\u064a\u0631 \u0645\u0646 CT. Ann Oncol \u0627\u0644\u0645\u062c\u0644\u062f 34 (\u0627\u0644\u0645\u0644\u062d\u0642 2): S1135-S1144\u060c 2196P. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>2) Kuon JB, Blasi M, Kokowski K, Faehling4 M, Schuette W, Christoph DCC, Kimmich M, Engel-Riedel W, Fischer JR, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum B\u00fcschenfelde C, Griesinger F, Schneider M, Behnisch R, Stenzinger A, Christopoulos P, Thomas M (2023): DURATION: \u062a\u062c\u0631\u0628\u0629 \u0639\u0634\u0648\u0627\u0626\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 II \u062a\u0633\u062a\u0642\u0635\u064a \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0623\u062d\u0627\u062f\u064a \u0627\u0644\u0645\u062a\u0633\u0644\u0633\u0644 (mCTX) \u0623\u0648 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u062b\u0646\u0627\u0626\u064a (dCTX) \u064a\u062a\u0628\u0639\u0647 \u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 (D) \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0623\u0643\u0628\u0631 \u0633\u0646\u064b\u0627 \u0623\u0648 \u0627\u0644\u0636\u0639\u0641\u0627\u0621 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 (NSCLC). Ann Oncol \u0627\u0644\u0645\u062c\u0644\u062f 34 (\u0627\u0644\u0645\u0644\u062d\u0642 2): S755-S851\u060c 1442P. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>3) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph DCCC (2023): \u062a\u062d\u062f\u064a\u0627\u062a \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u0647\u0627\u0632\u064a \u0643\u062e\u0637 \u0623\u0648\u0644 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0645\u0633\u0646\u064a\u0646. Ann Oncol \u0627\u0644\u0645\u062c\u0644\u062f 34 (\u0627\u0644\u0645\u0644\u062d\u0642 2): S755-S851\u060c 1483P. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>4) Evers G, Reitnauer LE, Christoph DCCC, Brueckl WM, Wiesweg M, Glanemann F, Webendoerfer M, Kropf C, Acker F, Hund A, Sch\u00fctte W, Hoffknecht P, Kerkhoff A, Mohr M, Lenz G, Frost N, Overbeck TR, Sebastian M, Bleckmann A (2023): \u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0641\u064a NSCLC \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0645\u0648\u0636\u0639\u064a\u064b\u0627 \u0627\u0644\u0646\u0627\u0643\u0633\/\u0627\u0644\u0645\u0642\u0627\u0648\u0645 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0648\u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 \u0627\u0644\u062a\u0648\u0637\u064a\u062f\u064a. Ann Oncol \u0627\u0644\u0645\u062c\u0644\u062f 34 (\u0627\u0644\u0645\u0644\u062d\u0642 2): S746-S754\u060c 1300P. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>5) Karthaus M, Christoph DC, Lux MP, Hofheinz RD, Jordan K (2023): \u062a\u0642\u064a\u064a\u0645 \u0641\u0627\u0626\u062f\u0629 NEPA (\u062a\u0631\u0643\u064a\u0628\u0629 \u062b\u0627\u0628\u062a\u0629 \u0645\u0646 Netupitant\/Palonosetron) \u0644\u0644\u0648\u0642\u0627\u064a\u0629 \u0645\u0646 \u0627\u0644\u063a\u062b\u064a\u0627\u0646 \u0648\u0627\u0644\u0642\u064a\u0621 \u0627\u0644\u0646\u0627\u062c\u0645\u064a\u0646 \u0639\u0646 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a (CINV) \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0630\u0648\u064a \u062e\u0637\u0631 \u0645\u0631\u062a\u0641\u0639 \u0644\u0644\u0642\u064a\u0621 \u0627\u0644\u0630\u064a\u0646 \u064a\u062a\u0644\u0642\u0648\u0646 \u0639\u0644\u0627\u062c\u064b\u0627 \u0643\u064a\u0645\u064a\u0627\u0626\u064a\u064b\u0627 \u0645\u062a\u0648\u0633\u0637 \u0627\u0644\u0625\u062d\u062f\u0627\u062b \u0644\u0644\u0642\u064a\u0621. Oncol Res and Treat 2023\u060c \u0627\u0644\u0645\u062c\u0644\u062f 46 (\u0627\u0644\u0645\u0644\u062d\u0642 5)\u060c P724. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>6) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph D (2023): \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u0647\u0627\u0632\u064a \u0643\u062e\u0637 \u0623\u0648\u0644 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0645\u0633\u0646\u064a\u0646: \u0627\u0644\u0627\u062e\u062a\u064a\u0627\u0631 \u0627\u0644\u0645\u0646\u0627\u0633\u0628 \u0635\u0639\u0628. Oncol Res and Treat 2023\u060c \u0627\u0644\u0645\u062c\u0644\u062f 46 (\u0627\u0644\u0645\u0644\u062d\u0642 5)\u060c P453. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>7) Reitnauer L, Evers G, Christoph D, Br\u00fcckl W, Wiesweg M, Glanemann F, Webend\u00f6rfer M, Kropf-Sanchen C, Acker F, Sch\u00fctte W, Hoff\u00acknecht P, Kerkho\u00ac A, Mohr M, Lenz G, Frost N, Overbeck T, Sebastian M, Bleckmann A (2023): \u0646\u0643\u0633 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0648\u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 \u0627\u0644\u062a\u0648\u0637\u064a\u062f\u064a \u0641\u064a NSCLC \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III \u2013 \u062a\u062d\u0644\u064a\u0644 \u0627\u0633\u062a\u0639\u0627\u062f\u064a \u0641\u064a \u0628\u064a\u0626\u0629 \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629. Oncol Res and Treat 2023\u060c \u0627\u0644\u0645\u062c\u0644\u062f 46 (\u0627\u0644\u0645\u0644\u062d\u0642 5)\u060c P451. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>8) Christoph D, Metzenmacher M, B\u00f6l\u00fckbas S, Volmerig J, Nilius G, Moka D, Hautzel H (2023): \u064a\u0643\u0634\u0641 PET-CT \u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0644\u0644\u0639\u0644\u0627\u062c \u0628\u0625\u064a\u0628\u064a\u0644\u064a\u0645\u0648\u0645\u0627\u0628 \u0648\u0646\u064a\u0641\u0648\u0644\u0648\u0645\u0627\u0628 \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062e\u0628\u064a\u062b \u0628\u0634\u0643\u0644 \u0623\u0641\u0636\u0644 \u0628\u0643\u062b\u064a\u0631 \u0645\u0646 CT. Oncol Res and Treat 2023\u060c \u0627\u0644\u0645\u062c\u0644\u062f 46 (\u0627\u0644\u0645\u0644\u062d\u0642 5)\u060c P446. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>9) Peters S, Christoph DC, Field JK, Fietkau R, Filippi AR, Garassino M, Garrido P, McDonald F, Mornex F, Markman B, Solomon BJ, Anand S, Chander P, Qiao Y, Girard N (2023): \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0645\u0639 \u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0641\u064a NSCLC \u063a\u064a\u0631 \u0627\u0644\u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0633\u062a\u0626\u0635\u0627\u0644 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III \u0645\u0639 \u0637\u0641\u0631\u0627\u062a EGFR (PACIFIC-R). J Thorac Oncol \u0627\u0644\u0645\u062c\u0644\u062f 18 \u0627\u0644\u0639\u062f\u062f 11 (\u0645\u0644\u062d\u0642)\u060c OA17.03. \u0639\u0631\u0636 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2023.<\/p>\n<p>10) Neal J, Pavlakis N, Kim S-W, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin A, Palmero R, Antic V, Chun E, Rao Edubilli T, Lin Y-C, Huseni M, Scheffold C, Vervaet P, Newsom-Davis T (2023): CONTACT-01: \u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629 \u0648\u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0645\u0646 \u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III \u0644\u0623\u062a\u064a\u0632\u0648\u0644\u064a\u0632\u0648\u0645\u0627\u0628 (atezo) + \u0643\u0627\u0628\u0648\u0632\u0627\u0646\u062a\u064a\u0646\u064a\u0628 (cabo) \u0645\u0642\u0627\u0628\u0644 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0623\u062d\u0627\u062f\u064a \u0628\u062f\u0648\u0633\u062a\u0627\u0643\u0632\u064a\u0644 (doc) \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 (pts) NSCLC \u0627\u0644\u0646\u0642\u064a\u0644\u064a (mNSCLC) \u0627\u0644\u0630\u064a\u0646 \u0639\u0648\u0644\u062c\u0648\u0627 \u0633\u0627\u0628\u0642\u064b\u0627 \u0628\u0645\u062b\u0628\u0637\u0627\u062a \u0646\u0642\u0627\u0637 \u0627\u0644\u062a\u0641\u062a\u064a\u0634 \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a. Journal of Thoracic Oncology\u060c \u0627\u0644\u0645\u062c\u0644\u062f 18 \u0627\u0644\u0639\u062f\u062f 4\u060c S39 &#8211; S40. \u0639\u0631\u0636 \u0641\u064a \u0645\u0624\u062a\u0645\u0631 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a 2023.<\/p>\n<p><strong>2022<\/strong><br \/>\n1) Girard N, Christoph DCC, Garassino MC, McDonald F, Mornex F, Field JK, Fietkau R, Garrido Lopez P, Haakensen VD, Siva S, Van den Heuvel M, Bar J, Chouaid C, Vercauter P, Chander P, Licour M, Anand S, de Lima ARMD, Filippi ARR (2022): \u0627\u0644\u0628\u0642\u0627\u0621 \u0627\u0644\u0643\u0644\u064a (OS) \u0641\u064a \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0645\u0639 \u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 (D) \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a (CRT) \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 (pts) \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 (NSCLC) \u063a\u064a\u0631 \u0627\u0644\u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0633\u062a\u0626\u0635\u0627\u0644 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III: \u062a\u062d\u0644\u064a\u0644 \u0645\u0631\u062d\u0644\u064a \u0645\u0646 \u062f\u0631\u0627\u0633\u0629 PACIFIC-R. Ann Oncol \u0627\u0644\u0645\u062c\u0644\u062f 16 (\u0627\u0644\u0645\u0644\u062d\u0642 1)\u060c O580. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0645\u0624\u062a\u0645\u0631 \u0639\u0644\u0645 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0645\u0646\u0627\u0639\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 2022.<\/p>\n<p>2) Galuba J, St\u00f6ver I, Koziorowski A, B\u00f6l\u00fckbas S, Nilius G, Christoph D (2022): \u0633\u0644\u0627\u0645\u0629 \u0648\u0641\u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0627\u0644\u0645\u064f\u062c\u0631\u0649 \u0628\u0627\u0644\u062a\u0632\u0627\u0645\u0646 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0630\u064a\u0646 \u064a\u062a\u0644\u0642\u0648\u0646 \u0639\u0644\u0627\u062c \u0623\u062a\u064a\u0632\u0648\u0644\u064a\u0632\u0648\u0645\u0627\u0628. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 45 (\u0627\u0644\u0645\u0644\u062d\u0642 3)\u060c P606. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u062e\u0627\u0645\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>3) Wessolly M, Mathilakathu A, Mairinger E, Nath A, Beckert H, Kreidt D, Klopp N, Heged\u00fcs B, Steinborn J, Hager T, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Borchert S, Schmid KW, FD Mairinger (2022): \u0645\u0633\u0627\u0631\u0627\u062a \u0627\u0644\u0625\u0634\u0627\u0631\u0629 \u0627\u0644\u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0646\u0634\u0627\u0637 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0644\u064a\u0641\u064a\u0629 \u0627\u0644\u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0627\u0644\u0633\u0631\u0637\u0627\u0646 \u062a\u0624\u062f\u064a \u0625\u0644\u0649 \u062a\u0642\u062f\u0645 \u0627\u0644\u0633\u0631\u0637\u0627\u0646 \u0648\u0632\u064a\u0627\u062f\u0629 \u062d\u0631\u0643\u064a\u0629 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0648\u0631\u0645\u064a\u0629 \u0641\u064a \u0648\u0631\u0645 \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0627\u0644\u062c\u0646\u0628\u064a \u0627\u0644\u062e\u0628\u064a\u062b. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 45 (\u0627\u0644\u0645\u0644\u062d\u0642 3) P416. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u062e\u0627\u0645\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>4) Kraus F, Nilius G, B\u00f6l\u00fckbas S, St\u00f6ver I, Koziorowski A, Grabellus F, Christoph DC (2022): \u0627\u0644\u0633\u0645\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0648\u0627\u0644\u0645\u0631\u0636\u064a\u0629 \u0648\u0625\u0646\u0630\u0627\u0631 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 (NSCLC) \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0633\u0631\u0637\u0627\u0646\u0627\u062a \u063a\u062f\u064a\u0629 \u062f\u0648\u0646 \u062a\u0639\u0628\u064a\u0631 TTF1 \u0648Napsin A. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 45 (\u0627\u0644\u0645\u0644\u062d\u0642 3)\u060c P433. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u062e\u0627\u0645\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>5) Christoph D, Girard N, Smit H.J.M, Sibille A, Mcdonald F, Mornex F, Garassino MC, Filippi AR, Peters S, Field JK, Drageset Haakensen V, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A; Licour M, Garrido P, Fietkau R (2022): \u062f\u0631\u0627\u0633\u0629 Pacific-R \u0641\u064a \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629: \u0645\u062f\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u0645\u0631\u062d\u0644\u064a \u0644\u0644\u0628\u0642\u0627\u0621 \u062f\u0648\u0646 \u062a\u0642\u062f\u0645 \u0627\u0644\u0645\u0631\u0636 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 NSCLC \u063a\u064a\u0631 \u0627\u0644\u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0633\u062a\u0626\u0635\u0627\u0644 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 III \u0627\u0644\u0645\u0639\u0627\u0644\u062c\u064a\u0646 \u0628\u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 45 (\u0627\u0644\u0645\u0644\u062d\u0642 3)\u060c P256. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u062e\u0627\u0645\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>6) Gr\u00f6schel A, Passlick B, Stuschke M., Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph D, Bernhardt C, Reiser M, M.-O. Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2022): \u0645\u0646\u0635\u0629 \u0623\u0628\u062d\u0627\u062b \u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u062a\u0642\u0635\u064a \u0627\u0644\u062c\u0632\u064a\u0626\u064a \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 (CRISP): \u0623\u0648\u0644 \u062f\u0644\u064a\u0644 \u0645\u0646 \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0644\u0645\u0631\u062d\u0644\u062a\u064e\u064a NSCLC II \u0648III \u0641\u064a \u0623\u0644\u0645\u0627\u0646\u064a\u0627 &#8211; AIO-TRK-0315. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 45 (\u0627\u0644\u0645\u0644\u062d\u0642 3)\u060c P135. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u062e\u0627\u0645\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>7) Zeuschner P, H\u00f6lters S, St\u00f6ckle M, Seliger B, M\u00fcller A, Bachmann HS, Gr\u00fcnwald V, Christoph DC, Stenzl A, Grimm M-O, Br\u00fcning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-R\u00fcd I, St\u00e4hler M, Junker K (2022): \u062b\u0631\u0648\u0645\u0628\u0648\u0633\u0628\u0648\u0646\u062f\u064a\u0646-2 \u0648LDH: \u0645\u0624\u0634\u0631\u0627\u062a \u062d\u064a\u0648\u064a\u0629 \u062a\u0646\u0628\u0624\u064a\u0629 \u0645\u062d\u062a\u0645\u0644\u0629 \u0644\u0639\u0644\u0627\u062c \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0643\u0644\u0648\u064a\u0629 \u0627\u0644\u0646\u0642\u064a\u0644\u064a \u0628\u0625\u064a\u0641\u064a\u0631\u0648\u0644\u064a\u0645\u0648\u0633 \u0628\u0639\u062f \u0639\u0644\u0627\u062c \u0648\u0627\u062d\u062f \u0645\u0648\u062c\u0651\u0647 \u0644\u0640 VEGF (\u062f\u0631\u0627\u0633\u0629 MARC-2). Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 45 (\u0627\u0644\u0645\u0644\u062d\u0642 3)\u060c P128. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u062e\u0627\u0645\u0633 \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>8) Eberhardt W, Passlick B, Stuschke M, Gr\u00f6schel A, Christopoulos P, Reck M, Ludwig P, Hipper A, Chiabudini M, Spring L, J\u00e4nicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Sebastian M, Griesinger F, Thomas M (2022): V899 \u0645\u0646\u0635\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0627\u0633\u062a\u0643\u0634\u0627\u0641 \u0627\u0644\u0641\u062d\u0648\u0635 \u0627\u0644\u062c\u0632\u064a\u0626\u064a\u0629 \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0645\u0633\u0627\u0631 \u0627\u0644\u0645\u0631\u0636 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 (CRISP): \u062f\u0644\u064a\u0644 \u0645\u0646 \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0644\u0645\u0631\u0636\u0649 NSCLC \u0627\u0644\u0645\u0639\u0627\u0644\u062c\u064a\u0646 \u0628\u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0641\u064a \u0623\u0644\u0645\u0627\u0646\u064a\u0627 &#8211; AIO-TRK-0315. Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 45 (\u0627\u0644\u0645\u0644\u062d\u0642 2)\u060c V899. \u0639\u0631\u0636 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>9) Sebastian M, Reck M, Fischer R, Christoph DC, Bernhardt C, von der Heyde E, Nusch A, Ludwig P, Hipper A, Hanselmann J, Medinger T, Binninger A, J\u00e4nicke M, Christopoulos P, Elender C, Bethge A, Seese B, Gauler T, Waller CF (2022): P327 \u0623\u0648\u0644 \u0628\u064a\u0627\u0646\u0627\u062a \u0646\u062a\u0627\u0626\u062c \u0645\u0646 \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0644\u0645\u0631\u0636\u0649 SCLC \u0641\u064a \u0623\u0644\u0645\u0627\u0646\u064a\u0627 \u2013 \u0628\u064a\u0627\u0646\u0627\u062a \u0645\u0646 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u062a\u0642\u0635\u064a \u0627\u0644\u062c\u0632\u064a\u0626\u064a \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 (\u063a\u064a\u0631) \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 (CRISP\u061b AIO-TRK-0315). Oncol Res Treat. \u0627\u0644\u0645\u062c\u0644\u062f 45 (\u0627\u0644\u0645\u0644\u062d\u0642 2)\u060c P327. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>10) Passlick B, Stuschke M, Gr\u00f6schel A, Christopoulos P, Reck M, Grah C, Hoffknecht P, Ludwig P, Hipper A, Chiabudini M, Spring L, J\u00e4nicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Nusch A, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2022): \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u062a\u0642\u0635\u064a \u0627\u0644\u062c\u0632\u064a\u0626\u064a \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 (CRISP): \u062f\u0644\u064a\u0644 \u0645\u0646 \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0644\u0645\u0631\u062d\u0644\u0629 NSCLC I \u0648II \u0648III \u0641\u064a \u0623\u0644\u0645\u0627\u0646\u064a\u0627 \u2013 AIO-TRK-0315. Zentralblatt f\u00fcr Chirurgie 147 (S01). V-130. \u0639\u0631\u0636 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGT.<\/p>\n<p>11) Sebastian M, Reck M, Fischer RN, Christoph DC, Bernhardt C, von der Heyde E, Nusch A, Ludwig P, Hipper A, Hanselmann J, Medinger T, Binninger A, J\u00e4nicke M, Christopoulos P, Elender C, Bethge A, Seese B, Gauler TC, Waller C (2022). \u0623\u0648\u0644 \u0628\u064a\u0627\u0646\u0627\u062a \u0646\u062a\u0627\u0626\u062c \u0645\u0646 \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0644\u0645\u0631\u0636\u0649 SCLC \u0641\u064a \u0623\u0644\u0645\u0627\u0646\u064a\u0627: \u0628\u064a\u0627\u0646\u0627\u062a \u0645\u0646 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u062a\u0642\u0635\u064a \u0627\u0644\u062c\u0632\u064a\u0626\u064a \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 (\u063a\u064a\u0631) \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 (CRISP\u061b AIO-TRK-0315). Ann Oncol. 33 (S7)\u060c P1542. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>12) Kuon JB, Blasi M, Kokowsk K, Faehling M, Schuette W, Christoph DC, Kimmich M, Engel-Riedel W, Fischer J, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum Bueschenfelde C, Griesinger F, Schneider M, Behnisch R, Stenzinger A, Christopoulos P, Thomas M (2022): DURATION &#8211; \u062a\u062c\u0631\u0628\u0629 \u0639\u0634\u0648\u0627\u0626\u064a\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 II \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0623\u0643\u0628\u0631 \u0633\u0646\u064b\u0627\/\u0627\u0644\u0636\u0639\u0641\u0627\u0621 (pts) \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 (NSCLC) \u062a\u0642\u0627\u0631\u0646 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a (CTX\u060c 4 \u062f\u0648\u0631\u0627\u062a) \u0645\u0639 CTX (\u062f\u0648\u0631\u062a\u0627\u0646) \u064a\u062a\u0628\u0639\u0647 \u062f\u0648\u0631\u0641\u0627\u0644\u0648\u0645\u0627\u0628 (D): \u0646\u0642\u0627\u0637 \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u0645\u0628\u0643\u0631\u0629 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629. Ann Oncol. 33 (S7)\u060c P1021. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>13) Eberhardt WEE, Passlick B Stuschke M, Groeschel A, Christopoulos P Reck M, Ludwig P, Hipper A, Chiabudini M, Spring L, J\u00e4nicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Sebastian M, Griesinger F, Thomas M (2022): \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u062a\u0642\u0635\u064a \u0627\u0644\u062c\u0632\u064a\u0626\u064a \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 (CRISP): \u062f\u0644\u064a\u0644 \u0645\u0646 \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0648\u0627\u0642\u0639\u064a\u0629 \u0644\u0645\u0631\u0636\u0649 NSCLC \u0627\u0644\u0645\u0639\u0627\u0644\u062c\u064a\u0646 \u0628\u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0625\u0634\u0639\u0627\u0639\u064a \u0627\u0644\u0643\u064a\u0645\u064a\u0627\u0626\u064a \u0641\u064a \u0623\u0644\u0645\u0627\u0646\u064a\u0627 \u2013 AIO-TRK-0315. Ann Oncol. 33 (S7)\u060c P963. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (ESMO).<\/p>\n<p>14) Stuschke M, Eberhardt W, Passlick B, Groeschel A, Christopoulos P, Reck M, Grah C, Hoffknecht P, Ludwig P, Hipper A, Chiabudini M, Spring L, Jaenicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Nusch A, Sebastian M, Griesinger F, Thomas M (2022): EP05.01-030 CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany &#8211; AIO-TRK-0315. J Thorac Oncol. Volume 17, Issue 9, Supplement. EP05.01. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2022.<\/p>\n<p><strong>2021<\/strong><br \/>\n1) Kuon J, Blasi M, Kokowski K, Faehling M, Sch\u00fctte W, Christoph DC, Kimmich M, Engel-Riedel W, Fischer JR, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum B\u00fcschenfelde C, Griesinger F, Fischer von Weikersthal L, Schmidt B, Gleiber W, Kirchen H, Werke M, R\u00fcckert A, Fr\u00f6hling K-P, Schmidtke-Schrezenmeier G, Moulin J-C, Denzlinger C, B\u00f6sche M, Groh\u00e9 C, Bernhard H, Maintz C, Heinrich K, Kern J, Schneider MA, Krisam J, Sternsinger A, Thomas M (2021): Durvalumab in frail and older patients with stage IV non-small cell lung cancer: the randomized phase II DURATION trial. J Cancer Res Clin Oncol. Volume 44 (Supplement 2), ep641. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>2) Galuba JM, Imke S, Koziorowski A, B\u00f6l\u00fckbas S, Nilius G, Christoph DC (2021): Efficacy and safety of simultaneously performed radiotherapy in patients with small-cell lung cancer undergoing Atezolizumab treatment. Oncol Res Treat. Volume 44 (Supplement 2), ep577. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>3) Kraus F, Nilius G, B\u00f6l\u00fckbas S, St\u00f6ver I, Koziorowski A, Grabellus F, Christoph D (2021): Clinical and pathological features and prognosis of non-small cell lung cancer (NSCLC) patients with adenocarcinomas without TTF1 and Napsin A expression. Oncol Res Treat. Volume 44 (Supplement 2), ep573. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>4) Shah R, Klotz LV, Christoph DC, Ried M, Wehler T, Reck M, Wesseler C, Bethge A, de Wit M, Hoffknecht P, J\u00fcrgens J, Kopp H-G, Hackanson B, Waller CF, Reinmuth N, Schneider MA, Krisam J, Christopoulos P, Eichhorn ME, Thomas M (2021): Nivolumab with chemotherapy in pleural mesothelioma after surgery \u2013 NICITA. Oncol Res Treat.Volume 44 (Supplement 2), ep253. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>5) Christoph DC, Girard N, Smit HJM, Sibille A, McDonald F, Mornex F, Garassino MC, Filippi AR, Peters S, Field JK, Drageset Haakensen V, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A, Licour M, Garrido P, Fietkau R (2021): Pacific-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with Durvalumab after chemoradiotherapy. Oncol Res Treat.Volume 44 (Supplement 2), V495. \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>6) Eberhardt WEE, Passlick B, Stuschke M, Gr\u00f6schel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, CRISP Registry Group (2021): Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC Stage II and III in Germany &#8211; AIO-TRK-0315: J Cancer Res Clin Oncol. Volume 44 (Supplement 2), V288. \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>7) Passlick B, Stuschke M, Gr\u00f6schel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph D, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2021): Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany \u2013 AIO-TRK-0315. Zentralblatt f\u00fcr Chirurgie 146 (S01). V-122. \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGT.<\/p>\n<p>8) Kraus F, Nilius G, B\u00f6l\u00fckbas S, St\u00f6ver I, Koziorowski A, Grabellus F, Christoph DC (2021): Clinical and pathological features and prognosis of nonsmall cell lung cancer (NSCLC) patients with adenocarcinomas without TTF1 and Napsin A expression. Ann Oncol. 32 (S5), P1812. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>9) Galuba JM, St\u00f6ver I, Koziorowski A, B\u00f6l\u00fckbas S, Nilius G, Christoph DC (2021): Safety of simultaneously performed radiotherapy in patients with small cell lung cancer undergoing atezolizumab treatment. Ann Oncol. 32 (S5), P1652. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>10) Gr\u00f6schel A, Passlick B, Stuschke M, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt WEE (2021): Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany &#8211; AIO-TRK-0315. Ann Oncol. 32 (S5), P1162. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>11) Girard N, Smit HJM, Sibille A, McDonald F, Mornex F, Garassino MCC, Filippi AR, Peters S, Field JK, Christoph DC, Fietkau R, Haakensen VD, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A, Licour M, Garrido P (2021): PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 32 (S5), MO1171. \u0645\u062d\u0627\u0636\u0631\u0629 \u0645\u0635\u063a\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>12) Galuba J, St\u00f6ver I, Koziorowski A, B\u00f6l\u00fckbas S, Nilius G, Christoph D (2021): Safety of Simultaneously Performed Radiotherapy in Patients With Small-Cell Lung Cancer Undergoing Atezolizumab Treatment. J Thorac Oncol. Volume 16, Issue 10, Supplement 1. P63.10. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2021.<\/p>\n<p>13) Kraus F, Nilius G, B\u00f6l\u00fckbas S, St\u00f6ver I, Koziorowski A, Grabellus F, Christoph D (2021): Pathological Features &#038; Prognosis of NSCLC Patients With Enteric Adenocarcinomas Without Expression of TTF-1 and Napsin A. J Thorac Oncol. Volume 16, Issue 10, Supplement 1. P56.04. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2021.<\/p>\n<p>14) Stuschke M, Passlick B, Gr\u00f6schel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt WE (2021): \u0645\u0646\u0635\u0629 \u0625\u0643\u0644\u064a\u0646\u064a\u0643\u064a\u0629 \u0644\u0644\u0628\u062d\u062b \u0641\u064a \u0627\u0644\u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u0627\u0644\u062c\u0632\u064a\u0626\u064a\u0629 \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0645\u0633\u0627\u0631 \u0627\u0644\u0645\u0631\u0636 \u0644\u0645\u0631\u0636\u0649 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 (CRISP): \u0623\u0648\u0644 \u062f\u0644\u064a\u0644 \u0648\u0627\u0642\u0639\u064a \u062d\u0648\u0644 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 \u063a\u064a\u0631 \u0635\u063a\u064a\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 (NSCLC) \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u062a\u064a\u0646 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0648\u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0641\u064a \u0623\u0644\u0645\u0627\u0646\u064a\u0627 &#8211; AIO-TRK-0315 (#175). Strahlentherapie und Onkologie Volume 197, supplement issue 1. VS01-2. \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DEGRO.<\/p>\n<p>15) Christoph DC, Ferdinandus J, Metzenmacher M, Kessler P, Umutlu L, Aigner C, Kambartel K-O, Gr\u00fcnwald V, Eberhardt WEE, Fendler WP, Herrmann K, Faehling M (2021). Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapy. Journal of Clinical Oncology 39:15 (supplement) 9050-9050. \u0645\u0646\u0627\u0642\u0634\u0629 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0645 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0633\u0631\u064a\u0631\u064a.<\/p>\n<p>16) McDonald F, Mornex F, Garassino MC, Filippi AR, Christoph D, Haakensen VD, Agbarya A, Van den Heuvel M, Vercauter P, Chouaid C, Pichon E, Siva S, Steinbusch L, Peretz I, Solomon B, Decoster L, Sawyer W, Allen A, Licour M, Girard N (2021): PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. J Thorac Oncol. Volume 16, Issue 4, Supplement 1. MO79. \u0645\u062d\u0627\u0636\u0631\u0629 \u0645\u0635\u063a\u0631\u0629 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2021.<\/p>\n<p><strong>2020<\/strong><br \/>\n1)Shah R, Klotz LV, Fei\u00dft M, Schneider M, Kriegsmann M, Ried M, Wesseler C, Christoph DC, de Wit M, J\u00fcrgens J, Kopp H-G, Wehler T, Reck M, Sackmann S, Waller C, Reinmuth N, Bischoff H, Winter H , Eichhorn M, Thomas M (2020): NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery. Ann Oncol. 31 (S4), TiP1912. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>2)Christoph DC, Rizzo F, Kambartel K-O, Winke S, Panse J, Abdulla DS, Scheffler M, Azeh IT, Hoiczyk M, Turki A, Metzenmacher M (2020): Docetaxel\/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence. Ann Oncol. 31 (S4), P1374. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>3)Christoph DC, Barbato F, Chodyla M-K, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Herrmann K, Ferdinandus J (2020): Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. Ann Oncol. 31 (S4), MO1896. \u0645\u062d\u0627\u0636\u0631\u0629 \u0645\u0635\u063a\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>4)Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska -Lange A, Aries SP, Sackmann S, Schuett P, Steger F, Christoph D (2020): Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP) Ann Oncol. 31 (S4), P1244. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>5)Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, P\u00e9rol M, Merle P, Sibille A, Markman B, Bouchaab H, Moskovitz M, Schumann C, Gregorc V, Klein AB, Diaz Perez I, Sawyer W, Licour M, Christoph D (2020): Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 31 (S4), P1242. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>6)Ferdinandus J, Barbato F, Chodyla M, Fendler W, Kessler L, Metzenmacher M, Krefting F, Hager T, Herrmann K, Christoph D (2020): PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab. Journal of Nuclear Medicine 61 (supplement 1) 243. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0637\u0628 \u0627\u0644\u0646\u0648\u0648\u064a \u0648\u0627\u0644\u062a\u0635\u0648\u064a\u0631 \u0627\u0644\u062c\u0632\u064a\u0626\u064a 2020.<\/p>\n<p><strong>2019<\/strong><br \/>\n1)Christoph D, Behringer D, Emde TO, Goekkurt E, Hinske C, Laack E, M\u00fcller-H\u00fcssmann H, Schlenska-Lange A, Sch\u00fctt P, Schumann C, Seese B, Fietkau R (2019): PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. Oncol Res Treat 42 (Suppl. 4), P757. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>2)Girard N, Mornex F, Christoph D, Fietkau R, Filippi A, Field J, Garrido Lopez P, McDonald F, Peters S, Klein A , Licour M, Garassino M (2019): PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. TiP 101. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2019.<\/p>\n<p>3)Christoph DC, Gettinger, S, Beck JT, Yang X, Telivala B, Morgensztern B, Velcheti V, Ramalingam S, Schalper K, Dajee M, Ranck A, Yang R, Spigel DR (2019): CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Der Pneumologe, P618. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p><strong>2018<\/strong><br \/>\n1)Staehler M, Christoph D, St\u00f6ckle M, Harde J, Stenzl A, Klein D, Benz-R\u00fcd I, Gr\u00fcnwald V (2018): Final results of phase IV study MARC-2: everolimus after failure of one prior VEGFR-tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. J Cancer Res Clin Oncol. Volume 41 (Supplement 4), P610. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>2)Nadjm S, Exner JP, Gauler T, P\u00f6ttgen C, Darwiche K, Cheufou D, Krebs B, Metzenmacher M, Oezkan F, Rebmann V, Umutlu L, Deusch C, Li Y, Lahner H, Christoph D, Hoiczyk M, Witzke O, Hoffmann AC, Aigner C, Theegarten D, Taube C, Schuler M, Stamatis G, Stuschke M, Eberhardt W (2018): Long-term Survival(LTS) and Survivorship Program(SS-P) of Lung Cancer(LC) Patients(Pts). Investigations(Invest) on LT-toxicities(Tox) and late morbidities(Morb). J Cancer Res Clin Oncol. Volume 41 (Supplement 3), P436. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u062b\u0627\u0644\u062b \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>3)Mairinger F, Schmeller J, Wessolly M, Mairinger E, Borchert S, Kollmeier J, Hager T, Mairinger T, Christoph D, Walter R, Pl\u00f6nes T, Wohlschl\u00e4ger J, Jasani B, Schmid KW, Bankfalvi A (2018): Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. J Cancer Res Clin Oncol. Volume 41 (Supplement 3), P406. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u062b\u0627\u0644\u062b \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>4)Mairinger F, Meier S, Wessolly M, K\u00f6hler C, Wagner F, Mairinger E, Schmeller J; Borchert S; Wohlschl\u00e4ger J, Pl\u00f6nes T, Hager T, Rozynek P, Kollmeier J, Christoph D, Schmid KW, Mairinger T, Johnen G, Walter R (2018): OncMass Spectrometry based Methylation Analysis of MDM2, CDKN2A, RB1, TP53 and TP73 and Associations to MDM2 Overexpression in Malignant Pleural mesothelioma. J Cancer Res Clin Oncol. Volume 41 (Supplement 3), P404. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064a \u0627\u0644\u062b\u0627\u0644\u062b \u0648\u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0646 \u0644\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>5)Mairinger FD, Schmeller J, Wessolly M, Mairinger E, Borchert S, Kollmeier J, Hager T, Christoph DC, Walter RFH, Eberhardt W, Pl\u00f6nes T, Wohlschl\u00e4ger J, Jasani B, Schmid KW, Bankfalvi A (2018): Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. Pathologe 39 (suppl. 1), AG03.P.09. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>6)S. Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC; Walter RF, Bankfalvi A, Eberhardt WEE, Pl\u00f6nes T, Wohlschl\u00e4ger J, Aigner C, Schmid KW, Mairinger FD (2018): BRCAness Ph\u00e4notyp als potentieller pr\u00e4diktiver Marker f\u00fcr neue Therapie-Strategien beim Malignen Pleuramesotheliom. Pathologe 39 (suppl. 1), AG03.P.08. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>7)Wessolly M, Schmeller J, Mairinger E, Borchert S, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Pl\u00f6nes8 T, Wohlschl\u00e4ger J, Schmid KW, Bankfalvi A, Mairinger1 FD (2018): miRNA regulation is important for DNA-damage repair and recognition in malignant pleural mesothelioma. Pathologe 39 (suppl. 1), AG-O303. \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p><strong>2017<\/strong><br \/>\n1)Stratmann JA, Hornetz S, Griesinger F, Wolf J, Christoph DC, Sackmann S, Spengler W, Bischoff H, Sch\u00e4fer M, Alt J, M\u00fcller A, Laack E, Kimmich M, Sebastian M (2017): An expanded access program of osimertinib (Tagrisso) in patients with advanced non-small cell lung cancer: data report from Germany. J Cancer Res Clin Oncol. Volume 40 (Supplement 3), P591. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>2)Oezkan F, Herold T, Darwiche K, Eberhardt W, Christoph D, Worm K, Freitag L, Schmid K, Hager T, Breitenbuecher F, Schuler M (2017): Rapid and highly sensitive EGFR del ex19 and KRAS exon 2 mutation detection in EBUS-TBNA sspecimen of lung adenocarcinoma. J Thorac Oncol. Volume 11, Issue 11, Supplement 1. P3.02B-025. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2016<\/p>\n<p>3)Mairinger FD, Werner R, Flom E, Vollbrecht C, Schmeller J, Borchert S, Wohlschlaeger J, Mairinger T, Kollmeier J, Christoph DC, Schmid KW, Walter RFH (2017): miRNA regulation is important for DNA-damage repair and recognition in malignant pleural mesothelioma. Pathologe 38 (suppl. 1), P-702. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>4)Vollbrecht C, Werner R, Walter RFH, Christoph DC, Heukamp, LC, Peifer M, Hirsch B, Burbat L, Mairinger T, Schmid KW, Wohlschlaeger J, Mairinger FD (2017): Mutational analysis of pulmonary tumors with neuroendocrine features using targeted paralell sequencing. Pathologe 38 (suppl. 1), P-0606. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>5)Garassino M, Rizvi N, Besse B, J\u00e4nne P, Christoph D, Peters S, Toh CK, Kurata T, Costa EC, Koczywas M, Felip E, Chaft J, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M (2017): Atezolizumab as 1L therapy for advanced NSCLC in PD-L1\u2013selected patients: updated ORR, PFS and OS data from the BIRCH study. J Thorac Oncol. Volume 12 Issue 1, Supplement 1. OA03.02. \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2016.<\/p>\n<p><strong>2016<\/strong><br \/>\n1)Wakelee H, Patel JD, Heist R, Balmanoukian A, Besse B, Felip E, Costa EC, Chow LQ, Koczywas M, Garassino MC, Christoph D, Toh CK, Johnson ML, Chaft J, Kurata T, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger SN, Peters S (2016): Phase II Trial of Atezolizumab for Patients with PD-L1\u2013Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results. J Thorac Oncol. Volume 11, Issue 11, Supplement 1. ORAL01.04. \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u201d\u0646\u062f\u0648\u0629 \u0634\u064a\u0643\u0627\u063a\u0648 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062a\u062e\u0635\u0635\u0627\u062a \u0641\u064a \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0635\u062f\u0631\u201c 2016.<\/p>\n<p><strong>2015<\/strong><br \/>\n1) Walter RFH, Vollbrecht C, Christoph DC, Werner R, Mairinger T, Theegarten D, Schmid KW, Wohlschlaeger J, Mairinger FD (2015): Investigation of Pharmaceutical Targets in Pulmonary Neuroendocrine Tumors by massive parallel sequencing and digital gene expression analysis. Pathologe 36 (suppl. 1), SO-069. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>2)Walter RFH, Werner R, Vollbrecht C, Theegarten D, Worm K, Mairinger T, Wohlschlaeger J, Christoph DC, Mairinger FD (2015): Nutlin-3A key players are differentially regulated through miRNAs between MDM2-positive and -negative pleural mesotheliomas. Pathologe 36 (suppl. 1), SO-018. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>3)Walter RFH, Mairinger F, Werner R, Vollbrecht C, Mairinger T, Worm K, Schmid KW, Christoph DC, Wohlschl\u00e4ger J (2015): Molecular Biological Analysis of Malignant Pleural Mesothelioma. Pathologe 36 (suppl. 1), SO-071. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p><strong>2014<\/strong><br \/>\n1)Walter RFH, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Stamatis G, Zwanziger D, Eberhardt W, Schuler M, Christoph DC, Freitag L, Schmid KW &#038; Wohlschlaeger J (2014): Screening 80 neuroendocrine lung cancer patients by using the NanoString technology implies several targets for new tailored therapies. Pathologe 35 (suppl. 1), SA-096. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>2)Walter RFH, Mairinger FD, Ting S, Vollbrecht C, Hager T, Worm K, Eberhardt W, Kollmeier J, Mairinger T, Christoph DC, Schmid KW, Freitag L &#038; Wohlschlaeger J (2014): Inhibition of MDM2 via Nutlin-3\u2014the next therapy for pleural mesothelioma with poor prognosis? Pathologe 35 (suppl. 1), SA-095. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>3)Mairinger F, Ting S, Werner R, Walter RFH, Hager T, Vollbrecht C, Christoph D, Worm K, Mairinger T, Sheu-Grabellus S-Y, Theegarten D, Schmid KW &#038; Wohlschlaeger J (2014): Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumours of the lung: results of a profiling study. Pathologe 35 (suppl. 1), SA-080. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>4)Walter RFH, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Stamatis G, Zwanziger D, Eberhardt W, Schuler M, Christoph DC, Freitag L, Schmid KW &#038; Wohlschlaeger J (2014): Is the mRNA expression profile of apoptosis and cell cycle related genes a marker for the aggressiveness of neuroendocrine tumors of the lung? Pathologe 35 (suppl. 1), FR-048. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>5)Mairinger F, Walter FRH, Werner R, Vollbrecht C, Ting S, Hager T, Schmid KW, Wohlschlaeger J &#038; Christoph D (2014): Folic acid metabolism and DNA-mismatch repair in pulmonary neuroendocrine tumors: identification of potential chemotherapy resistance mechanisms. Pathologe 35 (suppl. 1), FR-044. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>6)Mairinger F, Walter RFH, Werner R, Ting T, Hager T, Vollbrecht C, Theegarten D, Christoph D, Schmid KW &#038; Wohlschlaeger J (2014): Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carcinomas and is crucial for carcinoid tumorgenesis. Pathologe 35 (suppl. 1), FR-043. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p><strong>2013<\/strong><br \/>\n1)Mairinger F, Ting S, Vollbrecht C, Walter RFH, Kollmeier J, Grief S, Hager T, Mairinger T, Christoph D, Schmid KW &#038; Wohlschl\u00e4ger J (2013): P53 E3 ubiquitin protein ligase homolog (mouse) (MDM-2) immunoexpression is a strong predictor of poor overall survival in malignant pleural mesothelioma. Pathologe 34 (suppl. 1), FR-103. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>2)Mairinger F, Ting S, Worm K, Hager T, Wohlschl\u00e4ger J, Schmid KW &#038; Christoph D (2013): LH1, MSH2, MSH6 and ERCC1: DNA-mismatch repair proteins associated with response to platin- based chemotherapy in MPM? Pathologe 34 (suppl. 1), FR-078. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p>3)Mairinger F, Walter RFH, Hager T, Vollbrecht C, Christoph D, Worm K, Ting S, Schmid KW &#038; Wohlschl\u00e4ger J (2013): The proteasome subunits PSMA5 and PSMB4 are potent markers to discriminate between typical and atypical carcinoid tumors of the lung. Pathologe 34 (suppl. 1), DO-036. \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGP.<\/p>\n<p><strong>2012<\/strong><br \/>\n1)Christoph DC, Reyna Asuncion B, Hassan B, Maltzman J, O\u2019Shannessy D, Gauler TC, Wohlschlaeger J, Wynes MW, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): Significance of Folate Receptor alpha (FRA) and Thymidylate Synthase (TS) Expression in metastatic Non-Small Cell Lung Cancer Patients treated with Pemetrexed-based chemotherapy. Onkologie 36 (suppl. 6; abstr V125). \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p>2)Christoph DC, Reyna Asuncion B, Hassan B, Maltzman J, O\u2019Shannessy D, Gauler TC, Wynes MW, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): Investigation of Folate Receptor alpha and Thymidylate Synthase Proteins Expression in metastatic Non-Small Cell Lung Cancer Patients treated with Pemetrexed-based chemotherapy. J Thorac Oncol 10 (Suppl 2). \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u201d\u0646\u062f\u0648\u0629 \u0634\u064a\u0643\u0627\u063a\u0648 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062a\u062e\u0635\u0635\u0627\u062a \u0641\u064a \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0635\u062f\u0631\u201c 2012.<\/p>\n<p>3)Christoph DC, Reyna Asuncion B, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Welter S, Tran C, Hassan B, Loewendick H, Peglow A, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): Folylpoly-\u03b3-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC). Abstract 1713. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0633\u0631\u0637\u0627\u0646.<\/p>\n<p>4)Christoph DC, Reyna Asuncion B, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Welter S, Tran C, Hassan B, Loewendick H, Peglow A, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): Folylpoly-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC). Poster B6. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0645\u0624\u062a\u0645\u0631 AACR-IASLC \u0627\u0644\u0645\u0634\u062a\u0631\u0643 \u062d\u0648\u0644 \u0627\u0644\u0623\u0635\u0648\u0644 \u0627\u0644\u062c\u0632\u064a\u0626\u064a\u0629 \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629: \u0627\u0644\u0628\u064a\u0648\u0644\u0648\u062c\u064a\u0627 \u0648\u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u0637\u0628 \u0627\u0644\u0634\u062e\u0635\u064a\u060c \u0633\u0627\u0646 \u062f\u064a\u064a\u063a\u0648\u060c \u0643\u0627\u0644\u064a\u0641\u0648\u0631\u0646\u064a\u0627\u060c \u0627\u0644\u0648\u0644\u0627\u064a\u0627\u062a \u0627\u0644\u0645\u062a\u062d\u062f\u0629 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629.<\/p>\n<p><strong>2011<\/strong><br \/>\n1)Christoph DC, Kasper S, Gauler TC, Breitenbuecher F, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Schuler M, Hirsch FR, Eberhardt WEE &#038; Wohlschlaeger J (2011): Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer. Eur J Cancer 47 (suppl 4; abstr PP35). \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 EORTC-NCI-ASCO \u062d\u0648\u0644 \u201d\u0627\u0644\u0645\u0624\u0634\u0631\u0627\u062a \u0627\u0644\u062c\u0632\u064a\u0626\u064a\u0629 \u0641\u064a \u0627\u0644\u0633\u0631\u0637\u0627\u0646\u201c.<\/p>\n<p>2)Gauler TC, Poettgen C, Korfee S, Wagner H, Hepp R, Stamatis G, Christoph DC, Passlick B, Budach V, Seeber S, Wilke H, Stuschke M &#038; Eberhardt W (2011): Long-term survival (LTS) and competing risks within a prospective multicenter German randomized trial comparing induction (IND) chemotherapy (CTx) followed by concurrent (cc) chemoradiation (CTx\/RTx) plus surgery (S) (=TRIMODALITY) supplemented by PCI versus local treatment alone (S + RTx) in operable IIIA NSCLC. J Thorac Oncol. 6 (suppl 2; abstr 2575). \u0645\u062d\u0627\u0636\u0631\u0629 \u0645\u0635\u063a\u0631\u0629 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2011.<\/p>\n<p>3Poettgen C, Le Pechoux C, Gauler TC, Stuschke M, Grunenwald DH, Stamatis G, Bildat S, Krbek T, Christoph DC, Welter S, Fischer B, Hepp R, Theegarten D &#038; Eberhardt W (2011): 10-year long-term survival (LTS) of induction (IND) chemotherapy (CTx) with three cycles cisplatin(P)\/paclitaxel(T) followed by concurrent (cc) chemoradiation (CTx\/RTx) P\/etoposide (eto)\/45 Gy (1.5 Gy bid) plus surgery (S) \u2013 a multicenter phase-II trial (CISTAXOL). J Thorac Oncol. 6 (suppl 2; abstr 2.563). \u0645\u062d\u0627\u0636\u0631\u0629 \u0645\u0635\u063a\u0631\u0629 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2011.<\/p>\n<p>4)Christoph DC, Mascaux C, Wynes MW, Reyna Asuncion B, Wohlschlaeger J, Theegarten D, Gauler TC, Neumann V, Poettgen C, Tran C, Tannapfel A, Schuler M, Eberhardt WEE &#038; Hirsch FR (2011): Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma. J Thorac Oncol. 6 (suppl 2; abstr 2.480). \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2011.<\/p>\n<p>5)Eberhardt W, Hepp R, Gauler TC, Christoph DC, Hoffmann A-C, Theegarten D, Welter S, Schmid KW, Wohlschlaeger J, Passlick B, Le P\u00e9choux C, Stamatis G, Stuschke M &#038; Poettgen C (2011): Competing risks analysis and long-term survival (LTS) of patients (pts) with locally advanced (LAD) stage III non-small cell lung cancer (NSCLC) treated on sequential trimodality (TM) trials. J Thorac Oncol 6: 2011 (suppl 2; abstr 2.200). \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2011.<\/p>\n<p>6)Christoph DC, Wohlschlaeger J, Neumann V, Gauler TC, Poettgen C, Peglow A, Tannapfel A, Schuler M, Hirsch FR, Eberhardt WEE &#038; Theegarten D (2011): Impact of dihydrofolate reductase expression for clinical benefit from pemetrexed in malignant pleural mesothelioma. J Thorac Oncol. 6 (suppl 2; abstr 1.853). \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2011.<\/p>\n<p>7)Christoph DC, Kasper S, Gauler TC, Breitenbuecher F, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Schuler M, Hirsch FR, Eberhardt WEE &#038; Wohlschlaeger J (2011): Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer. J Thorac Oncol. 6 (suppl 2; abstr 2.227). \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2011.<\/p>\n<p>8)Christoph DC, Mascaux C, Wynes MW, Reyna Asuncion B, Wohlschlaeger J, Theegarten D, Gauler TC, Schuler M, Eberhardt WEE &#038; Hirsch FR (2011): Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma. J Clin Oncol. 29 (suppl; abstr 7024). \u0645\u0646\u0627\u0642\u0634\u0629 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0645 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0633\u0631\u064a\u0631\u064a.<\/p>\n<p>9)Christoph DC, Wittkowski L, Stattaus J, P\u00f6ttgen C, Keyvani K, Gauler TC, Schuler M &#038; Eberhardt WEE (2011): Very late and isolated leptomeningeal relapse of a pulmonary adenocarcinoma presenting as dementia. Onkologie 34 (suppl. 6; abstr P574). \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p><strong>2009<\/strong><br \/>\n1)Gauler TC, Christoph DC, Gamarra F, Fuhr H-G, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M &#038; Eberhardt WEE (2008): Phase I study of sagopilone (ZK-EPO) in combination with cisplatin in patients with chemotherapy-naive extensive disease small cell lung cancer (ED-SCLC). Ann Oncol. 19 (suppl 1: abstr 331P). \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u0645\u0646\u0638\u0645\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0644\u0633\u0631\u0637\u0627\u0646\/\u0627\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>2)Christoph DC, Gauler TC, Gamarra F, Fuhr H-G, Fischer JR, Gonschorek C, Frickhofen N, Huber RM, Schuler M &#038; Eberhardt WEE (2009): Phase I trial of sagopilone in combination with cisplatin as 1st-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC). Eur J Cancer Suppl. 7 (abstr Po9142). \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u0645\u0646\u0638\u0645\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0644\u0633\u0631\u0637\u0627\u0646\/\u0627\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0623\u0648\u0631\u0627\u0645.<\/p>\n<p>3)Gauler TC, Christoph DC, Gamarra F, Fuhr H-G, Fischer JR, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M &#038; Eberhardt WEE (2009): Phase I study of sagopilone (ZK-EPO) in combination with cisplatin in patients with chemotherapy-na\u00efve extensive-disease small-cell lung cancer (ED-SCLC). J Thorac Oncol. 4 (suppl 1; abstr PD4.4.1). \u0645\u0646\u0627\u0642\u0634\u0629 \u0645\u0644\u0635\u0642 \u0641\u064a \u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 2009.<\/p>\n<p><strong>2008<\/strong><br \/>\n1)Christoph DC, Gauler TC, Gamarra F, Fuhr H-G, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M &#038; Eberhardt WEE (2008): Phase I trial of sagopilone (ZK-EPO) in combination with cisplatin as first-line therapy in patients with extensive disease small-cell lung cancer (ED-SCLC). Onkologie 31 (suppl. 4; abstr V180). \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGHO \u0648OeGHO \u0648SGHSSH.<\/p>\n<p><strong>2004<\/strong><br \/>\n1)Schmidt M, Stope MB, Szatkowski DC, vom Dorp F, Oude Weernink PA &#038; Jakobs KH (2004): Epac and Ca2+-controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. N-S Arch Pharmacol. 371 (suppl 1; abstr R10). \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGPT \u0644\u0639\u0627\u0645 2003.<\/p>\n<p>2)Szatkowski DC, Keiper M, Stope MB, Oude Weernink PA, Jakobs KH &#038; Schmidt M (2004): PLC-\u03b5 and CalDAG2-mediated activation of Ras and MAP kinases by the \u03b22-Adrenoceptor. N-S Arch Pharmacol. 369 (suppl 1; abstr R203). \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGPT.<\/p>\n<p><strong>2003<\/strong><br \/>\n1)Szatkowski DC, B\u00f6hm A &#038; Schmidt M (2003): Molekulare Mechanismen der CalDAG3- und Rap2B-abh\u00e4ngigen Phospholipase C-e-Stimulation durch EGF. \u0639\u0631\u0636 \u0645\u0644\u0635\u0642 \u0641\u064a \u064a\u0648\u0645 \u0627\u0644\u0628\u062d\u062b \u0627\u0644\u062b\u0627\u0646\u064a \u0644\u0645\u0633\u062a\u0634\u0641\u0649 \u0625\u064a\u0633\u0646 \u0627\u0644\u062c\u0627\u0645\u0639\u064a (18-11-2003).<\/p>\n<p>2)Schmidt M, Keiper M, B\u00f6hm A, Evellin S, Sari A, Szatkowski DC, vom Dorp F, OudeWeernink, PA &#038; Jakobs KH (2003): Mechanisms of the CalDAG3- and Rap2B-mediated phospholipase C stimulation by the epidermal growth factor receptor. N-S Arch Pharmacol. 367 (suppl 1; abstr R195). \u0645\u062d\u0627\u0636\u0631\u0629 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0640 DGPT.<\/p>\n<\/div><\/div><\/div><\/section>\n<section class='av_toggle_section av-m194jok1-93ccc50fe19b0e41175605c33b529818'  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div role=\"tablist\" class=\"single_toggle\" data-tags=\"{All} \"  ><p id='toggle-toggle-id-2' data-fake-id='#toggle-id-2' class='toggler  av-title-above '  itemprop=\"headline\"  role='tab' tabindex='0' aria-controls='toggle-id-2' data-slide-speed=\"200\" data-title=\"\u0645\u0633\u0627\u0647\u0645\u0627\u062a \u0641\u064a \u0627\u0644\u0643\u062a\u0628\" data-title-open=\"\" data-aria_collapsed=\"Click to expand: \u0645\u0633\u0627\u0647\u0645\u0627\u062a \u0641\u064a \u0627\u0644\u0643\u062a\u0628\" data-aria_expanded=\"Click to collapse: \u0645\u0633\u0627\u0647\u0645\u0627\u062a \u0641\u064a \u0627\u0644\u0643\u062a\u0628\">\u0645\u0633\u0627\u0647\u0645\u0627\u062a \u0641\u064a \u0627\u0644\u0643\u062a\u0628<span class=\"toggle_icon\"><span class=\"vert_icon\"><\/span><span class=\"hor_icon\"><\/span><\/span><\/p><div id='toggle-id-2' aria-labelledby='toggle-toggle-id-2' role='region' class='toggle_wrap  av-title-above'  ><div class='toggle_content invers-color '  itemprop=\"text\" ><p><strong>2016<\/strong><br \/>\n1)Christoph DC &#038; Eberhardt WEE: Radiotherapy in the Elderly Cancer Patient (Chapter 6). In: Schrijvers D, Aapro M, Zakotnik B, Audisio R, van Halteren H, Hurria A. EUROPEAN SOCIETY OF MEDICAL ONCOLOGY HANDBOOK OF CANCER IN THE SENIOR PATIENT (2016). Informa Healthcare New York \u2013 London.<\/p>\n<p><strong>2012<\/strong><br \/>\n1)Eberhardt WEE, Krbek T, Theegarten D &#038; Christoph DC: Malignes Mesotheliom (Kapitel 19). In: Meyer J, Fleig WE, Pletz MW, Mayet W-J, Mertens P, M\u00fcller O-A, Pfeifer M, Weiss N &#038; Busse O. Rationelle Diagnostik und Therapie in der Inneren Medizin. Lieferung 35 Elsevier M\u00fcnchen.<\/p>\n<p><strong>2010<br \/>\n<\/strong>1)Christoph DC &#038; Eberhardt WEE: Radiotherapy in the Elderly Cancer Patient (Chapter 6). In: Schrijvers D, Aapro M, Zakotnik B, Audisio R, van Halteren H, Hurria A. EUROPEAN SOCIETY OF MEDICAL ONCOLOGY HANDBOOK OF CANCER IN THE SENIOR PATIENT (2010). Informa Healthcare New York \u2013 London.<\/p>\n<p><strong>2007<\/strong><br \/>\n1)Christoph D &#038; Christoph S. Gesundheitsst\u00f6rungen &#8211; Harntrakt (Chapter 10). In: Schaps K-P, Kessler O, Fetzner U. DAS ZWEITE \u2013 KOMPAKT (2007). Springer Heidelberg.<\/p>\n<p>2)Szatkowski D &#038; Schaps K-P. Innere Medizin &#8211; H\u00e4matologie, H\u00e4mostaseologie und internistische Onkologie (Chapter 7). In: Schaps K-P, Kessler O &#038; Fetzner U. DAS ZWEITE \u2013 KOMPAKT (2007). Springer Heidelberg.<\/p>\n<\/div><\/div><\/div><\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":4633,"menu_order":221,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5677","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/wp-json\/wp\/v2\/pages\/5677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/wp-json\/wp\/v2\/comments?post=5677"}],"version-history":[{"count":3,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/wp-json\/wp\/v2\/pages\/5677\/revisions"}],"predecessor-version":[{"id":5680,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/wp-json\/wp\/v2\/pages\/5677\/revisions\/5680"}],"up":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/wp-json\/wp\/v2\/pages\/4633"}],"wp:attachment":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/ar\/wp-json\/wp\/v2\/media?parent=5677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}